| Efficacy and safety of Glecaprevir/Pibrentasvir in patients with metabolic syndrome and HCV infection: An integrated analysis
|
Aghemo, A., Baumgarten, A., DeLedinghen, V., Jacobson, I., Lee, S. S., Saab, S., Kleine, H., De Michina, A., Lei, Y., Collins, C., Craxi, A.
|
2018
|
| Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease
|
Aglitti, A., Caruso, R., Calvanese, G., Di Siervi, P., Tripodi, M. F., Masarone, M., Persico, M.
|
2019
|
| Persistence of circulating cryoglobulins and related symptoms after hepatitis c virus eradication in patients with mixed cryoglobulin syndrome
|
Bassoli, C. R., Oreni, L., Sollima, S., Saccardo, F., Sebastiani, M., Vacchi, C., Mazzaro, C., Zani, R., Ferri, C., Zignego, A. L., Monti, G., Brancaccio, G., Gentile, I., Masarone, M., Gabiati, C., Pontali, E., Castelnovo, L., Messina, V., Galli, M.
|
2019
|
| Long-term immunological and clinical impact of HCVeradication with direct acting antivirals in patients with HCV-associated cryoglobulinemia vasculitis
|
Bonacci, M., Lens, S., Maro, Z., Rodriguez-Tajes, S., Bartres, C., Ramos-Casals, M., Hernndez-Rodrguez, J., Forns, X.
|
2018
|
| Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 45 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
|
Bruchfeld, A., Roth, D., Martin, P., Nelson, D. R., Pol, S., Londoo, M. C., Monsour, H., Silva, M., Hwang, P., Arduino, J. M., Robertson, M., Nguyen, B. Y., Wahl, J., Barr, E., Greaves, W.
|
2017
|
| Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C VirusAssociated Cryoglobulinemia Vasculitis
|
Cacoub, P., Si Ahmed, S. N., Ferfar, Y., Pol, S., Thabut, D., Hezode, C., Alric, L., Comarmond, C., Ragab, G., Quartuccio, L., Hegazy, M., Poynard, T., Resche Rigon, M., Saadoun, D.
|
2019
|
| Interferon-free antivirals for hepatitis c virus-associated cryoglobulinemia vasculitis: A long-term follow-up study
|
Cacoub, P., Si ahmed, S. N., Ferfar, Y., Pol, S., Thabut, D., Hezode, C., Alric, L., Comarmond, C., Ragab, G., Quatuccio, L., Hegazy, M., Poynard, T., Resche Rigon, M., Saadoun, D.
|
2018
|
| All oral interferon-free antivirals for hepatitis c virus cryoglobulinemia vasculitis: A long term follow up multicenter international study
|
Cacoub, P., Si Ahmed, S. N., FerFar, Y., Pol, S. N., Thabut, D., Hezode, C., Albric, L., Comarmond, C., Ragab, G., Quartuccio, L., Hegazy, M., Poynard, T., Resche-Rigon, M., Saadoun, D.
|
2017
|
| Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: An interim analysis on safety, efficacy and impact on quality of life
|
Cerretelli, G., Gragnani, L., Monti, M., Arena, U., Fognani, E., Petraccia, L., Gianni, E., Sollima, S., Brancaccio, G., Galli, M., Gaeta, G. B., Zignego, A. L.
|
2017
|
| Direct-acting antiviral-based therapy restores immune tolerance in hepatitis c-induced cryoglobulinemia vasculitis
|
Comarmond, C., Garrido, M., Desbois, A. C., Costopoulos, M., Le Garff-Tavernier, M., Si Ahmed, S. N., Alric, L., Fontaine, H., Bellier, B., Maciejewski, A., Rosenzwajg, M., Klatzmann, D., Musset, L., Poynard, T., Cacoub, P., Saadoun, D.
|
2017
|
| Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C VirusInduced Cryoglobulinemia Vasculitis
|
Comarmond, C., Garrido, M., Pol, S., Desbois, A. C., Costopoulos, M., Le Garff-Tavernier, M., Si Ahmed, S. N., Alric, L., Fontaine, H., Bellier, B., Maciejewski, A., Rosenzwajg, M., Klatzmann, D., Musset, L., Poynard, T., Cacoub, P., Saadoun, D.
|
2017
|
| Treatment of HCV-induced cryoglobulinemic vasculitis with new direct acting antiviral (DAA) regimens
|
Cristin, D., Wieland, A. C., Langness, J., Darling, J. M., Lim, J. K., Feld, J. J., Nelson, D. R., Fried, M. W., Vainorius, M., Morelli, G. J., Kuo, A., Everson, G. T.
|
2017
|
| Immunosuppressive treatment does not improve kidney survival in patients with hcv cryoglobulinaemia treated with direct-acting antivirals
|
Pérez de José, A, Carbayo, J., Pocurull, A., Huerta, A., Corona, C. M. C., Bosch, T. B., Shabaka, A., Terrada, N. R., Valenzuela, L. M., Goicoechea, M.
|
2020
|
| Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia
|
Diakite, M., Hartig-Lavie, K., Miailhes, P., Pradat, P., Uhres, A. C., Zoulim, F., Sarda, M. N.
|
2017
|
| Short course pre & post exposure DAA prophylaxis in hepatitis C negative recipients of hepatitis C nucleic acid positive kidney transplants
|
Durand, C., Barnaba, B., Brown, D., Bair, N., Naqvi, F., Bowring, M. G., Ostrander, D., Segev, D., Sulkowski, M. S., Massaccesi, G., Rousseau, K., Chattergoon, M. A., Desai, N. M.
|
2019
|
| Effect of anemia on efficacy and safety of chronic hepatitis c treatment among renal patients using direct acting anti-virus
|
Elmowafy, A., Abbas, M., Elmaghrabi, H., Soliman, R., Elwasif, S., Sheashaa, H., Shiha, G., Rostaing, L., Bakr, M.
|
2020
|
| Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt
|
Elsharkawy, A., Fouad, R., El Akel, W., El Raziky, M., Hassany, M., Shiha, G., Said, M., Motawea, I., El Demerdash, T., Seif, S., Gaballah, A., El Shazly, Y., Makhlouf, M. A. M., Waked, I., Abdelaziz, A. O., Yosry, A., El Serafy, M., Thursz, M., Doss, W., Esmat, G.
|
2017
|
| Immunosuppressive and antiviral treatment of hepatitis c virusassociated glomerular disease: A long-term follow-up
|
Fabrizi, F., Aghemo, A., Lampertico, P., Fraquelli, M., Cresseri, D., Moroni, G., Passerini, P., Donato, F. M., Messa, P.
|
2018
|
| Effects of IFN-free treatment on the virological, clinical, immunological, and quality-of-life in patients with hcv-related mixed cryoglobulinemia: A prospective and controlled study
|
Gragnani, L., Cerretelli, G., Monti, M., Petraccia, L., Sadalla, S., Steidl, C., Lorini, S., Giovannelli, A., Xheka, A., Caini, P., Simone, A., Arena, U., Zignego, A. L.
|
2017
|
| Treatment with pegylated interferon before transplantation improves posttransplant outcome in dialysis patients infected with HCV
|
Gulin, M., Juki, N. B.
|
2018
|
| Sofosbuvirdaclatasvir improves hepatitis C virus induced mixed cryoglobulinemia: Upper Egypt experience
|
Hassan, A. M., Osman, H. A., Mahmoud, H. S., Hassan, M. H., Hashim, A. K. A., Ameen, H. H.
|
2018
|
| DNA damage and repair in patients with cryoglobulinemic vasculitis treated with direct anti-HCV drugs
|
Hegazy, M. T., Allam, W., Hussein, M. A., Zoheir, N., Quartuccio, L., Cacoub, P., Doss, W., Ellawindi, M. I., Fawzy, M., Guillevin, L., El Ray, A., Raziky, M. E. S. E., Serafy, M. E., Khamisy, S. E., Ragab, G.
|
2018
|
| Relapsing cryoglobulinemic vasculitis following successful HCV eradication by interferon-free direct acting antivirals, an international multicenter study
|
Hegazy, M. T., Fayed, A., El Shabony, T., Visentini, M., Saadoun, D., Cacoub, P., Ragab, G.
|
2019
|
| Relapsing cryoglobulinemia vasculitis following successful HCV eradication by interferon-free direct acting antivirals, an international multicenter study
|
Hegazy, M. T., Fayed, A., Shabony, T. E., Visentini, M., Saadoun, D., Ragab, G., Cacoub, P.
|
2019
|
| The impact of ombitasvir/paritaprevir/ritonavir with dasabuvir in patients with HCV associated cryoglobulinemia-experience of a single center
|
Iliescu, E. L., Baciuureche, M., Mercan, A., Dodot, M., Dumitru, R., Toma, L.
|
|
| THE IMPACT OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH DASABUVIR IN PATIENTS WITH HCV ASSOCIATED CRYOGLOBULINEMIA- EXPERIENCE OF A SINGLE CENTER
|
Iliescu, E. L., Grumeza, M., Mercan, A., Toma, L., Dodot, M., Isac, T.
|
2019
|
| Management of patients with chronic kidney disease in the setting of interferon-free treatment for chronic HCV hepatitis
|
Iliescu, E. L., Ioanitescu, S., Toma, L., Ureche, M. B., Mercan-Stanciu, A., Iancu, C., Dodot, M.
|
2018
|
| Direct antivirus agents therapy reduce BETA2 microglobulin levels of the hemodialysis patients with hepatitis C virus infection
|
Ito, M.
|
2019
|
| Long term effectiveness of Daa therapy in patients with chronic HCV and mixed cryoglobulinemic syndrome
|
Kondili, L. A., Monti, M., Ferrante, G., Quaranta, M. G., Madia, F., Vinci, M., Borgia, G., Brancaccio, G., Coco, B., Margotti, M., Chemello, L., Ciancio, A., Rumi, M. G., Puoti, M., Madonia, S., Fracanzani, A. L., Persico, M., Filomia, R., Biliotti, E., Benedetti, A., Negri, E., Ieluzzi, D., Coppola, C., Santantonio, T. A., Zignego, A. L.
|
2019
|
| Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort
|
Kondili, L. A., Monti, M., Gaeta, G. B., Rizzo, V., Borgia, G., Zappulo, E., Chemello, L., Cavalletto, L., Vinci, M., Palladini, S., Andreone, P., Margotti, M., Puoti, M., Danieli, E., Persico, M., Masarone, M., Madonia, S., Brunetto, M. R., Coco, B., Ieluzzi, D., Passigato, N., Rumi, M. G., Sciola, V., Massari, M., Corsini, R., Mazzella, G., Lazzarini, G., Taliani, G., Biliotti, E., Andreoni, M., Cerva, C., Alberti, A., Gonzo, M., Chessa, L., Pasetto, M. C., Federico, A., Dallio, M., Quaranta, M. G., Weimer, L. E., Vella, S., Zignego, A. L.
|
2017
|
| Interleukin-17A and B-cell activating factor in chronic hepatitis c patients with or without asymptomatic mixed cryoglobulinemia: Effects of antiviral treatment and correlations with vitamin D
|
Konstantinides, P., Alexopoulou, A., Hadziyannis, E., Kanellopoulou, T., Dourakis, S. P.
|
2018
|
| Etiology of dysfunction in grafts from hepatitis c-infected donors
|
L'Imperio, V., Rossi, M., Paueksakon, P., Kapp, M.
|
2020
|
| Efficacy and Safety of Glecaprevir/Pibrentasvir in Renallyimpaired Patients with Chronic HCV Genotype 1-6 Infection
|
Lawitz, E., Flisiak, R., Abunimeh, M., Sise, M., Park, J. Y., Kaskas, M., Bruchfeld, A., Wrns, M. A., Aglitti, A., Xue, Z., Rullman, J., Porcalla, A. R., Cohen, E., Trinh, R. N., Persico, M.
|
2018
|
| Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers
|
Lorini, S., Gragnani, L., Santarlasci, V., Monti, M., Basile, U., Petraccia, L., Madia, F., Marri, S., Martini, L., Carradori, E., Xheka, A., Caini, P., Pellicelli, A., Cosmi, L., Annunziato, F., Zignego, A. L.
|
2019
|
| Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers
|
Lorini, S., Gragnani, L., Santarlasci, V., Monti, M., Basile, U., Petraccia, L., Madia, F., Marri, S., Martini, L., Carradori, E., Xheka, A., Caini, P., Pellicelli, A. M., Cosmi, L., Annunziato, F., Zignego, A. L.
|
2019
|
| B-Cell depletion therapy with rituximab in patients with hepatitis C virus mixed cryoglobulinemic vasculitis improves B- and T-Cell phenotype and function
|
Mathur, P., Emmanuel, B., Kottilil, S.
|
2017
|
| Mixed cryoglobulinemia, clinical data and therapy options of 246 cases: Monocentric study
|
Mazzaro, C., Mauro, E., Dal Maso, L., Ghersetti, M., Zorat, F., Gattei, V., Pozzato, G.
|
2018
|
| Systematic review with meta-analysis: Real-world effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in Asia
|
Nguyen, M., Wei, B., Yeo, Y. H., Ogawa, E., Stave, C., Dang, S., Li, Z., Furusyo, N., Zou, B., Cheung, R.
|
2018
|
| Real-life effectivness and safety of glecaprevir/pibrentasvir in HCV infected patients with chronic kidney disease
|
Persico, M., Aglitti, A., Caruso, R., Calvanese, G., Di Siervi, P., Grazia, N. M., Tripodi, M. F., Masarone, M.
|
2019
|
| Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infection
|
Persico, M., Flisiak, R., Abunimeh, M., Sise, M., Park, J. Y., Kaskas, M., Bruchfeld, A., Wrns, M. A., Aglitti, A., Xue, Z., Rullman, J., Pocalla, A., Lawitz, E.
|
2018
|
| Direct-acting antivirals (DAAs) treatment improves hepatitis C virus (HCV)-associated mixed cryoglobulinemia symptoms
|
Pollastri, E., Spinetti, A., Odolini, S., Tomasoni, L., Lanza, P. A., Bonito, A., Zaltron, S., Nasta, P., Urbinati, L., Biasi, L., Festa, E., Casari, S., Affatato, S., Belotti, E., Zani, R., Scaini, P., Cancarini, G., Castelli, F.
|
2017
|
| MAGELLAN-2: Safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection
|
Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Agarwal, K., Angus, P., Gane, E., Kao, J. H., Mantry, P. S., Reddy, K. R., Tran, T. T., Hu, Y. B., Gulati, A., Ng, T. I., Dumas, E. O., Shulman, N., Trinh, R., Forns, X.
|
2017
|
| Direct Acting Antivirals in patients with HCV-associated mixed cryoglobulinemia: Real life safety and efficacy
|
Rizzardini, G., Schiavini, M., Niero, F., Magni, C., Landonio, S., Iemoli, E., Bolis, M., Colaneri, M., Gubertini, G.
|
2017
|
| A randomized open-label trial of paritaprevir plus ritonavir plus ombitasvir in the treatment of HCV genotype 4-infected patients with stage 4-5 chronic kidney disease
|
Sanai, F., Babatin, M., Khan, M. Q., Alghamdi, H. S., Alswat, K. A., Aleid, H., Alqahtani, A., Albiladi, H., Alghamdi, A. S., Batwa, F. A., Aljumah, A. A., Alalwan, A. M., Aldarsouny, T., Basubiah, J., Abdo, A., Alashgar, H.
|
2018
|
| Off-label use of rituximab in patients with glomerulonephritis in a tertiary hospital: a retrospective observational study
|
Sans, C., Bosch, J., Agust, A., Dans, I., Agraz, I.
|
2019
|
| Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication
|
Sollima, S., Milazzo, L., Antinori, S., Galli, M.
|
2017
|
| Safety and efficacy of paritaprevir/r and ombitasvir combination therapy for HCV infected patients with Cryoglobulinemia
|
Suda, G., Terashita, K., Ogawa, K., Morikawa, K., Sakamoto, N.
|
2018
|
| Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis c virus-related cryoglobulinemic vasculitis, henoch-schnlein purpura, ankylosing spondylitis, and raynauds phenomenon
|
Taha, R., El-Haddad, H., Almuallim, A., Alshaiki, F., Obaid, E., Almoallim, H.
|
2017
|
| Safety of rituximab biosimilar for the treatment of cryoglobulinemic vasculitis
|
Vacchi, C., Visentini, M., Di Cicco, M., Angelotti, F., Lauletta, G., Manfredi, A., Filippini, D., Tavoni, A., Casato, M., Castelnovo, L., Monti, G., Pietrogrande, M., Salvarani, C., Galli, M., Sebastiani, M.
|
2019
|
| Therapy with direct acting antivirals in patients with hepatitis C virus related lymphoproliferative disorders and mixed cryogloglobulinemia
|
Venezia, L., Troshina, G., Tucci, A., Ponzo, P., Sacco, M., Smedile, A., Rizzetto, M., Saracco, G. M., Ciancio, A.
|
2017
|
| The Real-Eorld Israeli experience of treating mild and severe chronic hepatitis C patients with elbasvir/grazoprevir: A large multi-center cohort study
|
Zuckerman, E., Ashkenazi, E., Kovalev, Y., Cohen-ezra, O., Veitsman, E., Saadi, T., Carlebach, M., Hazzan, R., Safadi, R., Goldberg, T., Oren, R., Ashur, Y., Carmiel, M., Kitay, Y., Hadary, R., Abu-Mouch, S., Bruk, R., Menachem, Y., Katchman, H., Shibolet, O., Arbib, O. S., Shirin, H., Tur-Kaspa, R., Braun, M., Cohen-Naftaly, M., Shlomai, A.
|
2019
|
| The real-world israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) and genotype 4 (GT4) patients with advanced fibrosis with elbasvir\ grazoprevir: A large multi-center cohort
|
Zuckerman, E., Ashkenazi, E., Kovalev, Y., Cohen-Ezra, O., Veitsman, E., Saadi, T., Carlebach, M., Hazzan, R., Safadi, R., Goldberg-Clein, T., Oren, R., Ashur, Y., Carmiel, M., Kitay, Y., Hadari, R., Abu-Mouch, S. M., Bruk, R., Menachem, Y., Kathcman, H., Shibolet, O., Sneh, O., Shirin, H., Tur-Kaspa, R., Braun, M., Cohen-Naftaly, M., Shlomai, A.
|
2017
|
| Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study
|
Saadoun, D., Thibault, V., Si Ahmed, S. N., Alric, L., Mallet, M., Guillaud, C., Izzedine, H., Plaisier, A., Fontaine, H., Costopoulos, M., Le Garff-Tavernier, M., Hezode, C., Pol, S., Musset, L., Poynard, T., Cacoub, P.
|
2016
|
| Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min
|
Nazario, H. E., Ndungu, M., Modi, A. A.
|
2016
|
| Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation
|
Kamar, N., Marion, O., Rostaing, L., Cointault, O., Ribes, D., Lavayssire, L., Esposito, L., Del Bello, A., Mtivier, S., Barange, K., Izopet, J., Alric, L.
|
2016
|
| Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents
|
Sawinski, D., Kaur, N., Ajeti, A., Trofe-Clark, J., Lim, M., Bleicher, M., Goral, S., Forde, K. A., Bloom, R. D.
|
2016
|
| Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES
|
Butt, A. A., Yan, P., Shaikh, O. S., Chung, R. T., Sherman, K. E.
|
2016
|
| Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
|
Suda, G., Kudo, M., Nagasaka, A., Furuya, K., Yamamoto, Y., Kobayashi, T., Shinada, K., Tateyama, M., Konno, J., Tsukuda, Y., Yamasaki, K., Kimura, M., Umemura, M., Izumi, T., Tsunematsu, S., Sato, F., Terashita, K., Nakai, M., Horimoto, H., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K., Sakamoto, N.
|
2016
|
| Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study
|
Gragnani, L., Piluso, A., Urraro, T., Fabbrizzi, A., Fognani, E., Petraccia, L., Genovesi, A., Giubilei, L., Ranieri, J., Stasi, C., Monti, M., Zignego, A. L.
|
2017
|
| Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis
|
Toyoda, H., Kumada, T., Tada, T., Takaguchi, K., Ishikawa, T., Tsuji, K., Zeniya, M., Iio, E., Tanaka, Y.
|
2016
|
| Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function
|
Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., Liapakis, A., Nelson, D. R., Fried, M. W., Terrault, N. A.
|
2016
|
| Sofosbuvir antiviral therapy in HCV patients with severe renal failure
|
Rodrguez Gil, F. J., Prez Garrido, I.
|
2017
|
| Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis
|
Toyoda, H., Kumada, T., Tada, T., Takaguchi, K., Ishikawa, T., Tsuji, K., Zeniya, M., Iio, E., Tanaka, Y.
|
2016
|
| Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
|
Desnoyer, A., Pospai, D., L, M. P., Gervais, A., Heurgu-Berlot, A., Laradi, A., Harent, S., Pinto, A., Salmon, D., Hillaire, S., Fontaine, H., Zucman, D., Simonpoli, A. M., Muret, P., Larrouy, L., Bernard Chabert, B., Descamps, D., Yazdanpanah, Y., Peytavin, G.
|
2016
|
| Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
|
Pockros, P. J., Reddy, K. R., Mantry, P. S., Cohen, E., Bennett, M., Sulkowski, M. S., Bernstein, D. E., Cohen, D. E., Shulman, N. S., Wang, D., Khatri, A., Abunimeh, M., Podsadecki, T., Lawitz, E.
|
2016
|
| Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis
|
Miyazaki, R., Miyagi, K.
|
2016
|
| DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting
|
Beinhardt, S., Al Zoairy, R., Ferenci, P., Kozbial, K., Freissmuth, C., Stern, R., Stttermayer, A. F., Stauber, R., Strasser, M., Zoller, H., Watschinger, B., Schmidt, A., Trauner, M., Hofer, H., Maieron, A.
|
2016
|
| Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis
|
Goel, A., Bhadauria, D. S., Kaul, A., Prasad, N., Gupta, A., Sharma, R. K., Rai, P., Aggarwal, R.
|
2017
|
| Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients
|
Gevers, T. J., Burger, D., Schipper-Reintjes, E., Kooistra, M. P., Richter, C.
|
2016
|
| Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy
|
Sollima, S., Milazzo, L., Peri, A. M., Torre, A., Antinori, S., Galli, M.
|
2016
|
| Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study
|
Kawakami, Y., Imamura, M., Ikeda, H., Suzuki, M., Arataki, K., Moriishi, M., Mori, N., Kokoroishi, K., Katamura, Y., Ezaki, T., Ueno, T., Ide, K., Masaki, T., Ohdan, H., Chayama, K.
|
2016
|
| Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
|
Lin, M. V., Sise, M. E., Pavlakis, M., Amundsen, B. M., Chute, D., Rutherford, A. E., Chung, R. T., Curry, M. P., Hanifi, J. M., Gabardi, S., Chandraker, A., Heher, E. C., Elias, N., Riella, L. V.
|
2016
|
| Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia
|
Gragnani, L., Visentini, M., Fognani, E., Urraro, T., De Santis, A., Petraccia, L., Perez, M., Ceccotti, G., Colantuono, S., Mitrevski, M., Stasi, C., Del Padre, M., Monti, M., Gianni, E., Pulsoni, A., Fiorilli, M., Casato, M., Zignego, A. L.
|
2016
|
| Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation
|
Sawinski, D., Patel, N., Appolo, B., Bloom, R.
|
2017
|
| Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients
|
Eisenberger, U., Guberina, H., Willuweit, K., Bienholz, A., Kribben, A., Gerken, G., Witzke, O., Herzer, K.
|
2017
|
| Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study
|
Agarwal, S. K., Bhowmik, D., Mahajan, S., Bagchi, S.
|
2016
|
| Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir
|
Chayama, K., Hayes, C. N.
|
2017
|
| Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis
|
Saab, S., M, A. Jimenez, S, N. Bau, Choi, G., Durazo, F. A., M, M. El-Kabany, Han, S. B., Busuttil, R. W.
|
2017
|
| Reversal of end-stage renal failure using direct-acting antiviral agents for chronic hepatitis C
|
Mitchell, T., Chakera, A., Jeffrey, G. P., Adams, L. A., Garas, G., Jones, T., MacQuillan, G.
|
2016
|
| Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction
|
Nakamura, Y., Imamura, M., Kawakami, Y., Teraoka, Y., Daijo, K., Honda, F., Morio, K., Kobayashi, T., Nakahara, T., Nagaoki, Y., Kawaoka, T., Tsuge, M., Hiramatsu, A., Aikata, H., Hayes, C. N., Miki, D., Ochi, H., Chayama, K.
|
2017
|
| Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on Hemodialysis
|
Mogahed, E. A., Abdelaziz, H., Helmy, H., Ghita, H., Abdel Mawla, M. A., Hassanin, F., Fadel, F. I., El-Karaksy, H.
|
2016
|
| Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals
|
Bonacci, M., Lens, S., Londoo, M. C., Mario, Z., Cid, M. C., Ramos-Casals, M., Snchez-Tapias, J. M., Forns, X., Hernndez-Rodrguez, J.
|
2017
|
| Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2
|
Nishida, N., Kono, M., Minami, T., Chishina, H., Arizumi, T., Takita, M., Yada, N., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., Sakurai, T., Kudo, M.
|
2016
|
| Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure
|
Dumortier, J., Bailly, F., Pageaux, G. P., Vallet-Pichard, A., Radenne, S., Habersetzer, F., Gagnieu, M. C., Grang, J. D., Minello, A., Guillaud, O., Kamar, N., Alric, L., Leroy, V.
|
2017
|
| Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease
|
Morisawa, N., Koshima, Y., Satoh, J. I., Maruyama, Y., Kuriyama, S., Yokoo, T., Amemiya, M.
|
2017
|
| Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease
|
Kohli, A., Alshati, A., Georgie, F., Manch, R., Gish, R. G.
|
2016
|
| Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial
|
Colombo, M., Aghemo, A., Liu, H., Zhang, J., Dvory-Sobol, H., Hyland, R., Yun, C., Massetto, B., Brainard, D. M., McHutchison, J. G., Bourlire, M., Peck-Radosavljevic, M., Manns, M., Pol, S.
|
2017
|
| Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
|
Abad, S., Vega, A., Rincn, D., Hernndez, E., Mrida, E., Macas, N., Muoz, R., Milla, M., Luo, J., Lpez-Gmez, J. M.
|
2017
|
| Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication
|
Suarez Benjumea, A., Gonzalez-Corvillo, C., Sousa, J. M., Bernal Blanco, G., Suer Poblet, M., Perez Valdivia, M. A., Gonzalez Roncero, F. M., Acevedo, P., Gentil Govantez, M. A.
|
2016
|
| Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study
|
Gentil, M. A., Gonzlez-Corvillo, C., Perell, M., Zarraga, S., Jimnez-Martn, C., Lauzurica, L. R., Alonso, A., Franco, A., Hernndez-Marrero, D., Snchez-Fructuoso, A.
|
2016
|
| [Serum CXCL-10 level in chronic hepatitis C patients with cryoglobulinemia and its influence on antiviral therapy]
|
Fan, X. H., Deng, Z. H., Xu, X. Y.
|
2016
|
| Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis
|
Li, T., Qu, Y., Guo, Y., Wang, Y., Wang, L.
|
2017
|
| Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience
|
Muñoz-Gómez, R., Rincón, D., Ahumada, A., Hernández, E., Devesa, M. J., Izquierdo, S., Ortiz, M., Hernández-Albujar, A., Fernández-Rodríguez, C., Calvo, M., González, R., Lozano, M., Castellano, G., Fernández-Vázquez, I.
|
2017
|
| Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents
|
Lubetzky, M., Chun, S., Joelson, A., Coco, M., Kamal, L., Ajaimy, M., Gaglio, P., Akalin, E., De Boccardo, G.
|
2017
|
| Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With RenalDysfunction
|
Ishigami, M., Hayashi, K., Honda, T., Kuzuya, T., Ishizu, Y., Ishikawa, T., Nakano, I., Urano, F., Kumada, T., Yoshioka, K., Goto, H., Hirooka, Y.
|
2017
|
| Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C
|
Fernndez, I., Muoz-Gmez, R., Pascasio, J. M., Baliellas, C., Polanco, N., Esforzado, N., Arias, A., Prieto, M., Castells, L., Cuervas-Mons, V., Hernndez, O., Crespo, J., Calleja, J. L., Forns, X., Londoo, M. C.
|
2017
|
| Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis
|
Colantuono, S., Mitrevski, M., Yang, B., Tola, J., Carlesimo, M., De Sanctis, G. M., Fiorilli, M., Casato, M., Visentini, M.
|
2017
|
| Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4
|
Abad, S., Vega, A., Hernndez, E., Mrida, E., de Sequera, P., Albalate, M., Macas, N., Milla, M., Lpez-Gmez, J. M.
|
2017
|
| Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease
|
Kondo, C., Atsukawa, M., Tsubota, A., Shimada, N., Abe, H., Asano, T., Yoshizawa, K., Okubo, T., Chuganji, Y., Aizawa, Y., Iio, E., Tanaka, Y., Iwakiri, K.
|
2017
|
| Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection
|
Tavares, R. C. F., Feldner, Acca, Pinho, J. R. R., Uehara, S. N. O., Emori, C. T., Carvalho-Filho, R. J., Silva, I. S. S., Santana, R. A. F., de Castro, V. F. D., Castoli, G. T. F., Cristovo, C. U., Ferraz, Mlcg
|
2017
|
| Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus
|
Morales, A. L., Liriano-Ward, L., Tierney, A., Sang, M., Lalos, A., Hassan, M., Nair, V., Schiano, T., Satoskar, R., Smith, C.
|
2017
|
| Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports
|
Ponziani, F. R., Siciliano, M., Lionetti, R., Pasquazzi, C., Gianserra, L., D'Offizi, G., Gasbarrini, A., Pompili, M.
|
2017
|
| Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce
|
Hanif, F. M., Laeeq, S. M., Mandhwani, R. K., Luck, N. H., Aziz, T., Mehdi, S. H.
|
2017
|
| Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis
|
Comarmond, C., Garrido, M., Pol, S., Desbois, A. C., Costopoulos, M., Le Garff-Tavernier, M., Si Ahmed, S. N., Alric, L., Fontaine, H., Bellier, B., Maciejewski, A., Rosenzwajg, M., Klatzmann, D., Musset, L., Poynard, T., Cacoub, P., Saadoun, D.
|
2017
|
| Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis
|
Choudhary, N. S., Kumar, A., Bodh, V., Bansal, S. B., Sharma, R., Jain, M., Saigal, S., Saraf, N.
|
2017
|
| Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis
|
Saadoun, D., Pol, S., Ferfar, Y., Alric, L., Hezode, C., Si Ahmed, S. N., de Saint Martin, L., Comarmond, C., Bouyer, A. S., Musset, L., Poynard, T., Resche Rigon, M., Cacoub, P.
|
2017
|
| Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia
|
Emery, J. S., Kuczynski, M., La, D., Almarzooqi, S., Kowgier, M., Shah, H., Wong, D., Janssen, H. L. A., Feld, J. J.
|
2017
|
| Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study
|
Bhamidimarri, K. R., Ladino, M., Pedraza, F., Guerra, G., Mattiazzi, A., Chen, L., Ciancio, G., Kupin, W., Martin, P., Burke, G., Roth, D.
|
2017
|
| Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study
|
Akhil, M. S., Kirushnan, B., Martin, M., Arumugam, K., Ganesh Prasad, N. K., Ravichandran, R.
|
2018
|
| Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry
|
Welzel, T. M., Hinrichsen, H., Sarrazin, C., Buggisch, P., Baumgarten, A., Christensen, S., Berg, T., Mauss, S., Teuber, G., Stein, K., Deterding, K., van Bmmel, F., Heyne, R., John, C., Zimmermann, T., Lutz, T., Schott, E., Hettinger, J., Kleine, H., Knig, B., Hppe, D., Wedemeyer, H.
|
2017
|
| Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens
|
Puenpatom, A., Hull, M., McPheeters, J., Schwebke, K.
|
2017
|
| Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience
|
Lauletta, G., Russi, S., Pavone, F., Vacca, A., Dammacco, F.
|
2017
|
| Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
|
Atsukawa, M., Tsubota, A., Koushima, Y., Ikegami, T., Watanabe, K., Shimada, N., Sato, S., Kato, K., Abe, H., Okubo, T., Arai, T., Itokawa, N., Kondo, C., Mikami, S., Asano, T., Chuganji, Y., Matsuzaki, Y., Iwakiri, K.
|
2017
|
| Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era
|
Cacoub, P., Vautier, M., Desbois, A. C., Lafuma, A., Saadoun, D.
|
2017
|
| Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study
|
Saxena, V., Khungar, V., Verna, E. C., Levitsky, J., Brown, R. S., Jr., Hassan, M. A., Sulkowski, M. S., O'Leary, J. G., Koraishy, F., Galati, J. S., Kuo, A. A., Vainorius, M., Akushevich, L., Nelson, D. R., Fried, M. W., Terrault, N., Reddy, K. R.
|
2017
|
| Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience
|
Aggarwal, A., Yoo, E. R., Perumpail, R. B., Cholankeril, G., Kumari, R., Daugherty, T. J., Lapasaran, A. S., Ahmed, A.
|
2017
|
| Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan
|
Suda, G., Furusyo, N., Toyoda, H., Kawakami, Y., Ikeda, H., Suzuki, M., Arataki, K., Mori, N., Tsuji, K., Katamura, Y., Takaguchi, K., Ishikawa, T., Tsuji, K., Shimada, N., Hiraoka, A., Yamsaki, S., Nakai, M., Sho, T., Morikawa, K., Ogawa, K., Kudo, M., Nagasaka, A., Furuya, K., Yamamoto, Y., Kato, K., Ueno, Y., Iio, E., Tanaka, Y., Kurosaki, M., Kumada, T., Chayama, K., Sakamoto, N.
|
2018
|
| Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
|
Bruchfeld, A., Roth, D., Martin, P., Nelson, D. R., Pol, S., Londoo, M. C., Monsour, H., Jr., Silva, M., Hwang, P., Arduino, J. M., Robertson, M., Nguyen, B. Y., Wahl, J., Barr, E., Greaves, W.
|
2017
|
| Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis
|
Morisawa, N., Koshima, Y., Kuriyama, S., Matsuyama, M., Hayashi, N., Satoh, J. I., Amemiya, M., Yokoo, T.
|
2017
|
| [Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment]
|
Ignatova, T. M., Kozlovskaya, L. V., Gordovskaya, N. B., Chernova, O. A., Milovanova, S. Y., Novikov, P. I., Nekrasova, T. P., Beketova, T. V., Mukhin, N. A.
|
2017
|
| Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients
|
Taneja, S., Duseja, A., De, A., Kumar, V., Ramachandran, R., Sharma, A., Dhiman, R. K., Gupta, K. L., Chawla, Y.
|
2018
|
| Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study
|
Chen, K., Lu, P., Song, R., Zhang, J., Tao, R., Wang, Z., Zhang, W., Gu, M.
|
2017
|
| Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study
|
Lin, M. S., Chen, T. H., Lin, W. Y., Liu, C. H., Hsieh, Y. Y., Chiu, W. N., Chang, C. H., Chen, M. Y., Chung, C. M., Lin, Y. S.
|
2017
|
| Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
|
Shin, H. P., Park, J. A., Burman, B., Kozarek, R. A., Siddique, A.
|
2017
|
| Direct-acting antivirals for chronic hepatitis C
|
Jakobsen, J. C., Nielsen, E. E., Feinberg, J., Katakam, K. K., Fobian, K., Hauser, G., Poropat, G., Djurisic, S., Weiss, K. H., Bjelakovic, M., Bjelakovic, G., Klingenberg, S. L., Liu, J. P., Nikolova, D., Koretz, R. L., Gluud, C.
|
2017
|
| Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R+Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials
|
Mehta, D. A., Cohen, E., Charafeddine, M., Cohen, D. E., Bao, Y., Sanchez Gonzalez, Y., Tran, T. T.
|
2017
|
| Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study
|
Surendra, M., Raju, S. B., Sridhar, N., Vijay Kiran, B., Rajesh, G., Anvesh, G., Raju, N.
|
2018
|
| Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
|
Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bru, N., Brown, A., Pol, S., Leroy, V., Persico, M., Moreno, C., Colombo, M., Yoshida, E. M., Nelson, D. R., Collins, C., Lei, Y., Kosloski, M., Mensa, F. J.
|
2017
|
| Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
|
Kumada, H., Watanabe, T., Suzuki, F., Ikeda, K., Sato, K., Toyoda, H., Atsukawa, M., Ido, A., Takaki, A., Enomoto, N., Kato, K., Alves, K., Burroughs, M., Redman, R., Pugatch, D., Pilot-Matias, T. J., Krishnan, P., Oberoi, R. K., Xie, W., Chayama, K.
|
2018
|
| Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios
|
Goetsch, M. R., Tamhane, A., Varshney, M., Kapil, A., Overton, E. T., Towns, G. C., Franco, R. A.
|
2017
|
| Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection
|
Llenas-Garca, J., Padilla, S., Masi, M., Gutirrez, F.
|
2018
|
| Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis
|
Mathur, P., Emmanuel, B., Sneller, M., Zhang, X., Poonia, B., Kottilil, S.
|
2018
|
| Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis
|
He, Y. L., Yang, S. J., Hu, C. H., Dong, J., Gao, H., Yan, T. T., Liu, J. F., Yang, Y., Ren, D. F., Zhu, L., Zhao, Y. R., Chen, T. Y.
|
2018
|
| Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects
|
Kosloski, M. P., Zhao, W., Marbury, T. C., Preston, R. A., Collins, M. G., Pugatch, D., Mensa, F., Kort, J., Liu, W.
|
2018
|
| Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
|
Agarwal, S. K., Bagchi, S., Yadav, R. K.
|
2017
|
| High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease
|
Sanai, F. M., Alghamdi, A. S., Afghani, A. A., Alswat, K., AlZanbagi, A., Alghamdi, M. N., AlMousa, A., Aseeri, M., Assiri, A. M., Babatin, M. A.
|
2018
|
| Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
|
Arai, T., Atsukawa, M., Tsubota, A., Ikegami, T., Shimada, N., Kato, K., Abe, H., Okubo, T., Itokawa, N., Kondo, C., Mikami, S., Asano, T., Chuganji, Y., Matsuzaki, Y., Toyoda, H., Kumada, T., Iio, E., Tanaka, Y., Iwakiri, K.
|
2018
|
| Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens
|
Boglione, L., Cusato, J., Pinna, S. M., De Nicol, A., Cariti, G., Di Perri, G., D'Avolio, A.
|
2018
|
| Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min
|
Goel, A., Bhadauria, D. S., Kaul, A., Verma, P., Mehrotra, M., Gupta, A., Sharma, R. K., Rai, P., Aggarwal, R.
|
2019
|
| Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia
|
Ji, F., Wei, B., Yeo, Y. H., Ogawa, E., Zou, B., Stave, C. D., Li, Z., Dang, S., Furusyo, N., Cheung, R. C., Nguyen, M. H.
|
2018
|
| Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study
|
Fernandez-Ruiz, M., Polanco, N., Garca-Santiago, A., Muoz, R., Hernndez, A. M., Gonzlez, E., Mercado, V. R., Fernndez, I., Aguado, J. M., Praga, M., Andrs, A.
|
2018
|
| Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction
|
Cox-North, P., Hawkins, K. L., Rossiter, S. T., Hawley, M. N., Bhattacharya, R., Landis, C. S.
|
2017
|
| Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis
|
Mehta, R., Desai, K., Kabrawala, M., Nandwani, S., Shah, J., Desai, N., Parekh, V.
|
2018
|
| Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis
|
Fujii, H., Kimura, H., Kurosaki, M., Hasebe, C., Akahane, T., Yagisawa, H., Kato, K., Yoshida, H., Itakura, J., Sakita, S., Satou, T., Okada, K., Kusakabe, A., Kojima, Y., Kondo, M., Morita, A., Nasu, A., Tamada, T., Okushin, H., Kobashi, H., Tsuji, K., Joko, K., Ogawa, C., Uchida, Y., Mitsuda, A., Sohda, T., Ide, Y., Izumi, N.
|
2018
|
| Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease
|
Taneja, S., Duseja, A., De, A., Mehta, M., Ramachandran, R., Kumar, V., Kohli, H. S., Gupta, K. L., Dhiman, R. K., Chawla, Y.
|
2018
|
| Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial
|
Durand, C. M., Bowring, M. G., Brown, D. M., Chattergoon, M. A., Massaccesi, G., Bair, N., Wesson, R., Reyad, A., Naqvi, F. F., Ostrander, D., Sugarman, J., Segev, D. L., Sulkowski, M., Desai, N. M.
|
2018
|
| 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease
|
Garca-Agudo, R., Aoufi-Rabih, S., Salgueira-Lazo, M., Gonzlez-Corvillo, C., Fabrizi, F.
|
2018
|
| Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up
|
Fabrizi, F., Aghemo, A., Lampertico, P., Fraquelli, M., Cresseri, D., Moroni, G., Passerini, P., Donato, F. M., Messa, P.
|
2018
|
| Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal
|
Weigert, A., Querido, S., Carvalho, L., Lebre, L., Chagas, C., Matias, P., Birne, R., Nascimento, C., Jorge, C., Adrago, T., Bruges, M., Machado, D.
|
2018
|
| Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network
|
Flamm, S. L., Bacon, B., Curry, M. P., Milligan, S., Nwankwo, C. U., Tsai, N., Younossi, Z., Afdhal, N.
|
2018
|
| Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort
|
Sperl, J., Kreidlova, M., Merta, D., Chmelova, K., Senkerikova, R., Frankova, S.
|
2018
|
| Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
|
Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Jr., Agarwal, K., Angus, P., Gane, E., Kao, J. H., Mantry, P. S., Mutimer, D., Reddy, K. R., Tran, T. T., Hu, Y. B., Gulati, A., Krishnan, P., Dumas, E. O., Porcalla, A., Shulman, N. S., Liu, W., Samanta, S., Trinh, R., Forns, X.
|
2018
|
| Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease
|
Manoj, Kumar, Nayak, S. L., Gupta, E., Kataria, A., Sarin, S. K.
|
2018
|
| Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials
|
Zamor, P. J., Vierling, J., Ghalib, R., Luketic, V., Ravendhran, N., Balart, L., Robertson, M., Hwang, P., Hanna, G. J., Nguyen, B. Y., Barr, E., Talwani, R., Pearlman, B.
|
2018
|
| The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes
|
Axelrod, D. A., Schnitzler, M. A., Alhamad, T., Gordon, F., Bloom, R. D., Hess, G. P., Xiao, H., Nazzal, M., Segev, D. L., Dharnidharka, V. R., Naik, A. S., Lam, N. N., Ouseph, R., Kasiske, B. L., Durand, C. M., Lentine, K. L.
|
2018
|
| Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure
|
Bonacci, M., Lens, S., Mario, Z., Londoo, M. C., Rodriguez-Tajes, S., Snchez-Tapias, J. M., Ramos-Casals, M., Hernndez-Rodrguez, J., Forns, X.
|
2018
|
| Treatment for hepatitis C virus-associated mixed cryoglobulinaemia
|
Montero, N., Fav, A., Rodriguez, E., Barrios, C., Cruzado, J. M., Pascual, J., Soler, M. J.
|
2018
|
| Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective
|
Alric, L., Ollivier-Hourmand, I., Brard, E., Hillaire, S., Guillaume, M., Vallet-Pichard, A., Bernard-Chabert, B., Loustaud-Ratti, V., Bourlire, M., de Ledinghen, V., Fouchard-Hubert, I., Canva, V., Minello, A., Nguyen-Khac, E., Leroy, V., Saadoun, D., Trias, D., Pol, S., Kamar, N.
|
2018
|
| Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
|
Mazzaro, C., Maso, L. D., Mauro, E., Gattei, V., Ghersetti, M., Bulian, P., Moratelli, G., Grassi, G., Zorat, F., Pozzato, G.
|
2018
|
| Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study
|
Chascsa, D. M., Mousa, O. Y., Pungpapong, S., Zhang, N., Chervenak, A., Nidamanuri, S., Rodriguez, E., Franco, D., Ryland, K., Keaveny, A. P., Huskey, J. L., Smith, M., Reddy, K. S., Taner, C. B., Vargas, H. E., Aqel, B. A.
|
2018
|
| Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
|
Sharma, S., Mukherjee, D., Nair, R. K., Datt, B., Rao, A.
|
2018
|
| Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study
|
Butt, A. A., Ren, Y., Puenpatom, A., Arduino, J. M., Kumar, R., Abou-Samra, A. B.
|
2018
|
| Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system
|
Kramer, J. R., Puenpatom, A., Erickson, K. F., Cao, Y., Smith, D., El-Serag, H. B., Kanwal, F.
|
2018
|
| Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis
|
Cacoub, P., Si Ahmed, S. N., Ferfar, Y., Pol, S., Thabut, D., Hezode, C., Alric, L., Comarmond, C., Ragab, G., Quartuccio, L., Hegazy, M., Poynard, T., Resche Rigon, M., Saadoun, D.
|
2019
|
| The Efficacy and Safety of Sofosbuvir/Ledipasvir Therapy in Patients on Long-term Hemodialysis with Hepatitis C Virus Infection
|
Cavoli, G. L., Schillaci, O., Zagarrigo, C., Servillo, F., Li Cavoli, T. V., Palmeri, M., Rotolo, U.
|
2018
|
| Effectiveness and safety of sofosbuvir/ledipasvirribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience
|
Akin, M., Buldukoglu, O. C., Adanir, H., Suleymanlar, I., Dincer, D., Yildirim, B.
|
2018
|
| Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan
|
Suzuki, F., Hatanaka, N., Bando, E., Nakamura, K., Komoto, A.
|
2018
|
| Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation
|
Reddy, S., Sharma, R. K., Mehrotra, S., Prasad, N., Gupta, A., Kaul, A., Singh Bhadauria, D.
|
2018
|
| Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis
|
Gragnani, L., Cerretelli, G., Lorini, S., Steidl, C., Giovannelli, A., Monti, M., Petraccia, L., Sadalla, S., Urraro, T., Caini, P., Xheka, A., Simone, A., Arena, U., Matucci-Cerinic, M., Vergani, D., Laffi, G., Zignego, A. L.
|
2018
|
| Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center
|
Prasad, N., Patel, M. R., Pandey, A., Jaiswal, A., Bhadauria, D., Kaul, A., Sharma, R. K., Mohindra, S., Pandey, G., Goel, A., Gupta, A.
|
2018
|
| Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection
|
Suda, G., Kurosaki, M., Itakura, J., Izumi, N., Uchida, Y., Mochida, S., Hasebe, C., Abe, M., Haga, H., Ueno, Y., Masakane, I., Abe, K., Takahashi, A., Ohira, H., Furuya, K., Baba, M., Yamamoto, Y., Kobayashi, T., Kawakami, A., Kumagai, K., Terasita, K., Ohara, M., Kawagishi, N., Umemura, M., Nakai, M., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K., Sakamoto, N.
|
2019
|
| Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation
|
Mansour, M., Hill, L., Kerr, J.
|
2018
|
| Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial
|
Reese, P. P., Abt, P. L., Blumberg, E. A., Van Deerlin, V. M., Bloom, R. D., Potluri, V. S., Levine, M., Porrett, P., Sawinski, D., Nazarian, S. M., Naji, A., Hasz, R., Suplee, L., Trofe-Clark, J., Sicilia, A., McCauley, M., Gentile, C., Smith, J., Niknam, B. A., Bleicher, M., Reddy, K. R., Goldberg, D. S.
|
2018
|
| Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry
|
Dultz, G., Mller, T., Petersen, J., Mauss, S., Zimmermann, T., Muche, M., Simon, K. G., Berg, T., Zeuzem, S., Hppe, D., Bker, K., Wedemeyer, H., Welzel, T. M.
|
2018
|
| Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency
|
Singh, A., Kumari, S., Kumar, P., De, A., Singh, V.
|
2018
|
| Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience
|
Passerini, M., Schiavini, M., Magni, C. F., Landonio, S., Niero, F., Passerini, S., Croci, A. L., Bolis, M., Scalzi, V., Gubertini, G., Ricci, E. D., Galli, M., Rizzardini, G.
|
2018
|
| Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study
|
Atsukawa, M., Tsubota, A., Toyoda, H., Takaguchi, K., Kondo, C., Okubo, T., Hiraoka, A., Michitaka, K., Fujioka, S., Uojima, H., Watanabe, T., Ikeda, H., Asano, T., Ishikawa, T., Matsumoto, Y., Abe, H., Kato, K., Tsuji, K., Ogawa, C., Shimada, N., Iio, E., Mikami, S., Tanaka, Y., Kumada, T., Iwakiri, K.
|
2019
|
| Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease
|
Mekky, M. A., Abdel-Malek, M. O., Osman, H. A., Abdel-Aziz, E. M., Hashim, A. A., Hetta, H. F., Morsy, K. H.
|
2019
|
| Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life
|
Sabbatini, M., Capuano, I., Camera, S., Ferreri, L., Buonanno, P., Donnarumma, L., Caporaso, N., Morisco, F.
|
2018
|
| Successful Treatment of Chronic Hepatitis C Virus Infection with Sofosbuvir and Ledipasvir in Renal Transplant Recipients: Erratum
|
Eisenberger, U.
|
2018
|
| Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
|
Kao, C. C., Lin, Y. S., Chu, H. C., Fang, T. C., Wu, M. S., Kang, Y. N.
|
2018
|
| Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia
|
Maduell, F., Belmar, L., Ugalde, J., Laguno, M., Martnez-Rebollar, M., Ojeda, R., Arias, M., Rodas, L., Rossi, F., Llovet, L. P., Gonzlez, L. N., Mallolas, J., Londoo, M. C.
|
2019
|
| Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease
|
Ogawa, E., Furusyo, N., Azuma, K., Nakamuta, M., Nomura, H., Dohmen, K., Satoh, T., Kawano, A., Koyanagi, T., Ooho, A., Takahashi, K., Kato, M., Shimoda, S., Kajiwara, E., Hayashi, J.
|
2018
|
| Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials
|
Tran, T. T., Mehta, D., Mensa, F., Park, C., Bao, Y., Sanchez Gonzalez, Y.
|
2018
|
| Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients
|
Huang, H., Tang, H., Deng, H., Shen, J., Zhou, Q., Xie, W., Wu, J., Chen, J.
|
2019
|
| The long-term impact of hepatitis C infection in kidney transplantation in the pre-direct acting antiviral era
|
Radhakrishnan, R. C., Gopal, B., Zachariah, U. G., Abraham, P., Mohapatra, A., Valson, A. T., Alexander, S., Jacob, S., Tulsidas, K. S., David, V. G., Varughese, S.
|
2018
|
| Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
|
Lee, B. S., Song, M. J., Kwon, J. H., Lee, T. H., Jang, J. W., Kim, S. H., Lee, S. H., Kim, H. S., Kim, J. H., Kim, S. B., Ko, S. Y., Song, D. S.
|
2019
|
| Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|
D'Ambrosio, R., Pasulo, L., Puoti, M., Vinci, M., Schiavini, M., Lazzaroni, S., Soria, A., Gatti, F., Menzaghi, B., Aghemo, A., Capelli, F., Rumi, M. G., Morini, L., Giorgini, A., Pigozzi, M. G., Rossini, A., Maggiolo, F., Pan, A., Memoli, M., Spinelli, O., Del Poggio, P., Saladino, V., Spinetti, A., De Bona, A., Capretti, A., Uberti-Foppa, C., Bonfanti, P., Terreni, N., Menozzi, F., Colombo, A. E., Giglio, O., Centenaro, R., Borghi, M., Baiguera, C., Picciotto, V., Landonio, S., Gori, A., Magnani, C., Noventa, F., Paolucci, S., Lampertico, P., Fagiuoli, S.
|
2019
|
| Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection
|
Otsuka, T., Kawaguchi, Y., Mizuta, T., Ide, Y., Koga, F., Kumagai, T., Yoshioka, W., Murayama, K., Rikitake, O., Ikeda, Y., Ozaki, I.
|
2017
|
| Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study
|
Gendia, M., Lampertico, P., Alfieri, C. M., D'Ambrosio, R., Gandolfo, M. T., Campise, M. R., Fabrizi, F., Messa, P.
|
2019
|
| Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function
|
Eisenberger, U., Friebus-Kardash, J., Guberina, H., Kribben, A., Witzke, O., Willuweit, K., Gerken, G., Herzer, K.
|
2019
|
| Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey
|
Yaraş, S., Üçbilek, E., Özdoğan, O., Ateş, F., Altıntaş, E., Sezgin, O.
|
2019
|
| Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences
|
Örmeci , N., Sezgin, O., Karaali, R., Aygen, B., Turan, D., Yaras, S., Erdem,, Yildiz, O., Karakaya, F., Ate, K., Asiller,
|
2019
|
| A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
|
Duerr, M., Schrezenmeier, E. V., Lehner, L. J., Bergfeld, L., Glander, P., Marticorena Garcia, S. R., Althoff, C. E., Sack, I., Brakemeier, S., Eckardt, K. U., Budde, K., Halleck, F.
|
2019
|
| Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients
|
Etik, Ö.D., Suna, N., Öcal, S., Selçuk, H., Dağlı, Ü, Çolak, T., Hilmioğlu, F., Boyacoğlu, A. S., Haberal, M.
|
2019
|
| Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD
|
Zhang, H., Xu, H., Wu, R., Yu, G., Sun, H., Lv, J., Wang, X., Chi, X., Gao, X., Kong, F., Zhang, M., Hang, L., Jiang, J., Pan, Y., Niu, J.
|
2019
|
| Experience with antiviral agents for treatment of hepatitis C virus infection in hemodialysis patients on the kidney wait list
|
Torun, D., Soydas, B., Tekkarismaz, N., Ozelsancak, R., Micozkadioglu, H., Haberal, M.
|
2019
|
| Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease
|
Lawitz, E., Gane, E., Cohen, E., Vierling, J., Agarwal, K., Hassanein, T., Mantry, P. S., Pockros, P. J., Bennett, M., Kemmer, N., Morelli, G., Zha, J., Wang, D., Shulman, N. S., Cohen, D. E., Reddy, K. R.
|
2019
|
| Treatment of Chronic Hepatitis C Infection Among Egyptian Kidney Transplant Recipients: A Pilot Study
|
El Maghrabi, H. M., Elmowafy, A. Y., Donia, A. F., Ismail, M. I., El-Hendy, Y. A., Soliman, R., Shiha, G. E., Bakr, M. A.
|
2019
|
| Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan
|
Hanif, F. M., Mandhwani, R., Lail, G., Luck, N. H., Aziz, T.
|
2019
|
| Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection
|
Suda, G., Hasebe, C., Abe, M., Kurosaki, M., Itakura, J., Izumi, N., Uchida, Y., Mochida, S., Haga, H., Ueno, Y., Abe, K., Takahashi, A., Ohira, H., Tsukuda, Y., Furuya, K., Baba, M., Yamamoto, Y., Kobayashi, T., Inoue, J., Terasita, K., Ohara, M., Kawagishi, N., Izumi, T., Nakai, M., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K., Sakamoto, N.
|
2019
|
| Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort
|
Said, M., Omar, H., Soliman, Z., Saad, Y., Dabes, H., Hamed, S., ElSaeed, K., ElShazly, Y., ElSerafy, M.
|
2019
|
| HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis
|
Wang, J., Hu, C., Chen, Y., Liu, Z., Yu, Q., Yang, S., Dong, J., Yang, Y., Wu, Y., Ren, D., Yao, N., Guo, D., Tian, Z., Zhao, Y., Chen, T., He, Y., Liu, J.
|
2019
|
| Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study
|
Ogawa, E., Furusyo, N., Nakamuta, M., Nomura, H., Satoh, T., Takahashi, K., Koyanagi, T., Kajiwara, E., Dohmen, K., Kawano, A., Ooho, A., Azuma, K., Kato, M., Shimoda, S., Hayashi, J.
|
2019
|
| Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis
|
Li, M., Chen, J., Fang, Z., Li, Y., Lin, Q.
|
2019
|
| The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study
|
Atsukawa, M., Tsubota, A., Toyoda, H., Takaguchi, K., Nakamuta, M., Watanabe, T., Michitaka, K., Ikegami, T., Nozaki, A., Uojima, H., Fukunishi, S., Genda, T., Abe, H., Hotta, N., Tsuji, K., Ogawa, C., Tachi, Y., Shima, T., Shimada, N., Kondo, C., Akahane, T., Aizawa, Y., Tanaka, Y., Kumada, T., Iwakiri, K.
|
2019
|
| Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients
|
D'Ambrosio, R., Vinci, M., Franchina, M., Parlati, L., Zaltron, S., Pasulo, L., Campise, M., Messa, P., Pol, S., Lampertico, P.
|
2019
|
| Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease
|
Gane, E., Poordad, F., Zadeikis, N., Valdes, J., Lin, C. W., Liu, W., Asatryan, A., Wang, S., Stedman, C., Greenbloom, S., Nguyen, T., Elkhashab, M., Wrns, M. A., Tran, A., Mulkay, J. P., Setze, C., Yu, Y., Pilot-Matias, T., Porcalla, A., Mensa, F. J.
|
2019
|
| Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu, C. H., Shih, Y. L., Yang, S. S., Lin, C. L., Fang, Y. J., Cheng, P. N., Chen, C. Y., Peng, C. Y., Hsieh, T. Y., Chiu, Y. C., Su, T. H., Liu, C. J., Yang, H. C., Chen, P. J., Chen, D. S., Kao, J. H.
|
2019
|
| Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation
|
Musialik, J., Kolonko, A., Kwiecie, K., Owczarek, A. J., Wicek, A.
|
2019
|
| Impact of grazoprevir and elbasvir in the treatment of hepatitis C virus-infected patients with chronic kidney disease and end-stage renal disease
|
Pedraza, F., Ladino, M., Roth, D.
|
2016
|
| Use of HCV Ab+/NAT- donors in HCV nave renal transplant recipients to expand the kidney donor pool
|
Dao, A., Cuffy, M., Kaiser, T. E., Loethen, A., Cafardi, J., Luckett, K., Rike, A. H., Cardi, M., Alloway, R. R., Govil, A., Diwan, T., Sherman, K. E., Shah, S. A., Woodle, E. S.
|
2019
|
| Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study
|
Persico, M., Aglitti, A., Milella, M., Coppola, C., Messina, V., Claar, E., Gentile, I., Sogari, F., Pierri, P., Surace, L. A., Morisco, F., Tundo, P., Brancaccio, G., Serviddio, G., Gatti, P., Termite, A. P., Di Costanzo, G. G., Caroleo, B., Cozzolongo, R., Coppola, N., Longo, A., Fontanella, L., Federico, A., Rosato, V., Terrenato, I., Masarone, M.
|
2019
|
| Sofosbuvir/velpatasvir for 12weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
|
Borgia, S. M., Dearden, J., Yoshida, E. M., Shafran, S. D., Brown, A., Ben-Ari, Z., Cramp, M. E., Cooper, C., Foxton, M., Rodriguez, C. F., Esteban, R., Hyland, R., Lu, S., Kirby, B. J., Meng, A., Markova, S., Dvory-Sobol, H., Osinusi, A. O., Bruck, R., Ampuero, J., Ryder, S. D., Agarwal, K., Fox, R., Shaw, D., Haider, S., Willems, B., Lurie, Y., Calleja, J. L., Gane, E. J.
|
2019
|
| Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents
|
Yan, T., Wang, J., Li, J., Fu, S., Chen, Y., Hu, C., Zhang, R., Tian, Z., Zhao, F., Dong, J., Liu, J., Yang, Y., Chen, T., Zhao, Y., He, Y.
|
2019
|
| Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study
|
Cheng, Y. T., Cheng, J. S., Lin, C. H., Chen, T. H., Lee, K. C., Chang, M. L.
|
2020
|
| Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals
|
Chen, Y. C., Li, C. Y., Tsai, S. J., Chen, Y. C.
|
2019
|
| Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis
|
Wang, X., Fan, X., Deng, H., Zhang, X., Zhang, K., Li, N., Han, Q., Lv, Y., Liu, Z.
|
2019
|
| Safety of Direct-Acting Antiviral Therapy for Renal Function in Post-Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response: A Single-Center Study
|
Kawagishi, N., Nakamura, A., Takayama, T., Haga, I.
|
2020
|
| Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience
|
Molnar, M. Z., Nair, S., Cseprekal, O., Yazawa, M., Talwar, M., Balaraman, V., Podila, P. S. B., Mas, V., Maluf, D., Helmick, R. A., Campos, L., Nezakatgoo, N., Eymard, C., Horton, P., Verma, R., Jenkins, A. H., Handley, C. R., Snyder, H. S., Cummings, C., Agbim, U. A., Maliakkal, B., Satapathy, S. K., Eason, J. D.
|
2019
|
| Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
|
Zhang, J., Sun, W., Lin, J., Tian, Y., Ma, L., Zhang, L., Zhu, Y., Qiu, W.
|
2019
|
| Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality
|
Elmowafy, A. Y., El Maghrabi, H. M., Eldahshan, K. F., Refaie, A. F., Elbasiony, M. A., Matter, Y. E., Saleh, H. H., Shiha, G. E., Rostaing, L., Bakr, M. A.
|
2019
|
| Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
|
Daniş, N., Toz, H., Unal, N., Yilmaz, M., Turan, I, Gunsar, F., Karasu, Z., Ersoz, G., Ozkahya, M., Akarca, U. S.
|
2019
|
| Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin
|
Chen, C. C., Tung, S. Y., Wei, K. L., Shen, C. H., Chang, T. S., Chen, W. M., Xu, H. W., Yen, C. W., Chen, Y. H., Lu, S. N., Hung, C. H.
|
2020
|
| Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
|
Cannon, R. M., Locke, J. E., Orandi, B. J., Anderson, D. J., Davis, E. G., Mackelaite, L., Dave, H., Eng, M., Jones, C. M.
|
2020
|
| Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients
|
El Maghrabi, H. M., Elmowafy, A. Y., Refaie, A. F., Elbasiony, M. A., Shiha, G. E., Rostaing, L., Bakr, M. A.
|
2019
|
| Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
|
Huff, J., Andersen, R.
|
2020
|
| Effectiveness, safety/tolerability of OBV/PTV/r DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study
|
Londoño, M. C., Riveiro-Barciela, M., Ahumada, A., Muñoz-Gomez, R., Roget, M., Devesa-Medina, M. J., Serra, M. A., Navascues, C. A., Baliellas, C., Aldamiz-Echevarria, T., Gutierrez, M. L., Polo-Lorduy, B., Carmona, I., Benlloch, S., Bonet, L., Garcia-Samaniego, J., Jiminez-Perez, M., Moran-Sanchez, S., Castro, A., Delgado, M., Gea-Rodriguez, F., Martin-Granizio, I., Montes, M. L., Morano, L., Castaño, M. A., de Los Santos, I., Laguno, M., Losa, J. E., Montero-Alonso, M., Rivero, A., de Alvaro, C., Manzanares, A., Mallolas, J., Barril, G., Gonzalez-Parra, E., Garcia-Buey, L.
|
2019
|
| Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)
|
Wiegand, J., Buggisch, P., Mauss, S., Boeker, K. H. W., Klinker, H., Mller, T., Gnther, R., Serfert, Y., Manns, M. P., Zeuzem, S., Berg, T., Hinrichsen, H., GH, C. Registry
|
2019
|
| Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment
|
Daniel, K. E., Saeian, K., Rizvi, S.
|
2020
|
| High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents
|
Elmowafy, A. Y., El Maghrabi, H. M., Mashaly, M. E., Eldahshan, K. F., Rostaing, L., Bakr, M. A.
|
2019
|
| Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients
|
Gupta, G., Yakubu, I., Bhati, C. S., Zhang, Y., Kang, L., Patterson, J. A., Andrews-Joseph, A., Alam, A., Ferreira-Gonzalez, A., Kumar, D., Moinuddin, I. K., Kamal, L., King, A. L., Levy, M., Sharma, A., Cotterell, A., Reichman, T. W., Khan, A., Kimball, P., Stiltner, R., Baldecchi, M., Brigle, N., Gehr, T., Sterling, R. K.
|
2020
|
| Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience
|
Kapila, N., Menon, K. V. N., Al-Khalloufi, K., Vanatta, J. M., Murgas, C., Reino, D., Ebaid, S., Shaw, J. J., Agrawal, N., Rhazouani, S., Navas, V., Sheffield, C., Rahman, A. U., Castillo, M., Lindenmeyer, C. C., Miller, C., Quintini, C., Zervos, X. B.
|
2020
|
| Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation
|
Wu, S. H., Loong, C. C., Chu, C. J., Su, C. W., Lin, C. C., Hsia, C. Y., Liu, C., Lee, S. D., Wang, Y. J., Lee, F. Y., Linb, N. C., Chen, C. Y., Huang, Y. H., Hou, M. C.
|
2020
|
| Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
|
Butt, N., Abbasi, A., Ali Khan, M., Ali, M., Mahesar, G. B., Haleem, F., Manan, A.
|
|
| Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4
|
Zarbska-Michaluk, D., Jaroszewicz, J., Buczyska, I., Simon, K., Lorenc, B., Tudrujek-Zdunek, M., Tomasiewicz, K., Sitko, M., Garlicki, A., Janczewska, E., Dybowska, D., Halota, W., Pawowska, M., Pabjan, P., Mazur, W., Czau-Andrzejuk, A., Berak, H., Horban, A., Socha,, Klapaczyski, J., Piekarska, A., Blaszkowska, M., Belica-Wdowik, T., Dobracka, B., Tronina, O., Dero, Z., Biakowska-Warzecha, J., Laurans,, Flisiak, R.
|
2020
|
| Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes
|
Rossato, G., Tovo, C. V., Almeida, P. R. L.
|
2020
|
| Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
|
Cheema, S. U. R., Rehman, M. S., Hussain, G., Cheema, S. S., Gilani, N.
|
2019
|
| Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study
|
Crismale, J. F., Khalid, M., Bhansali, A., De Boccardo, G., Khaim, R., Florman, S. S., Shapiro, R., Schiano, T. D.
|
2020
|
| Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study
|
D'Ambrosio, R., Pasulo, L., Giorgini, A., Spinetti, A., Messina, E., Fanetti, I., Puoti, M., Aghemo, A., Vigan, P., Vinci, M., Menzaghi, B., Lombardi, A., Pan, A., Pigozzi, M. G., Grossi, P., Lazzaroni, S., Spinelli, O., Invernizzi, P., Maggiolo, F., Terreni, N., Monforte, A. D., Poggio, P. D., Taddei, M. T., Colombo, S., Pozzoni, P., Molteni, C., Brocchieri, A., Bhoori, S., Buscarini, E., Centenaro, R., Mendeni, M., Colombo, A. E., Di Marco, M., Dionigi, E., Bella, D., Borghi, M., Zuin, M., Zaltron, S., Noventa, F., Annalisa, S., Lampertico, P., Fagiuoli, S.
|
2020
|
| Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection
|
Lawitz, E., Flisiak, R., Abunimeh, M., Sise, M. E., Park, J. Y., Kaskas, M., Bruchfeld, A., Wrns, M. A., Aglitti, A., Zamor, P. J., Xue, Z., Schnell, G., Jalundhwala, Y. J., Porcalla, A., Mensa, F. J., Persico, M.
|
2020
|
| Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment
|
Eletreby, R., El-Serafy, M., Anees, M., Kasem, G., Salama, M., Elkhouly, R., Hamdy, M., Abdel Haleem, H., Kamal, E., Abdel-Razek, W., Salama, R., Elshenawy, M., Shafeek, A., Hassany, M., El-Sayed, M. H., El-Shazly, Y., Esmat, G.
|
2020
|
| Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
|
Choi, D. T., Puenpatom, A., Yu, X., Erickson, K. F., Kanwal, F., El-Serag, H. B., Kramer, J. R.
|
2020
|
| Clinical outcomes of hepatitisC virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study
|
Morishita, A., Ogawa, C., Moriya, A., Tani, J., Yoneyama, H., Fujita, K., Oryu, M., Senoo, T., Takaguchi, K., Masaki, T.
|
2020
|
| Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
|
Iliescu, E. L., Mercan-Stanciu, A., Toma, L.
|
2020
|
| Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu, C. H., Yang, S. S., Peng, C. Y., Lin, W. T., Liu, C. J., Su, T. H., Tseng, T. C., Chen, P. J., Chen, D. S., Kao, J. H.
|
2020
|
| Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience
|
Tatar, B., Kse,, Ergun, N. C., Turken, M., Onlen, Y., Ylmaz, Y., Akhan, S.
|
2019
|
| The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment
|
Poustchi, H., Majd Jabbari, S., Merat, S., Sharifi, A. H., Shayesteh, A. A., Shayesteh, E., Minakari, M., Fattahi, M. R., Moini, M., Roozbeh, F., Mansour-Ghanaei, F., Afshar, B., Mokhtare, M., Amiriani, T., Sofian, M., Somi, M. H., Agah, S., Maleki, I., Latifnia, M., Fattahi Abdizadeh, M., Hormati, A., Khoshnia, M., Sohrabi, M., Malekzadeh, Z., Merat, D., Malekzadeh, R.
|
2020
|
| Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access
|
Graham, J. A., Torabi, J., Ajaimy, M., Akalin, E., Liriano, L. E., Azzi, Y., Pynadath, C., Greenstein, S. M., Goldstein, D. Y., Fox, A. S., Weiss, J. M., Powell, T. P., Reinus, J. F., Kinkhabwala, M. M., Rocca, J. P.
|
2020
|
| Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study
|
Gonzalez-Corvillo, C., Beneyto, I., Sanchez-Fructuoso, A., Perell, M., Alonso, A., Mazuecos, A., Jiminez, C., Zarraga, S., Paul, J., Lauzurica, R., Hernandez, D., Guirado, L., Franco, A., Ruiz, J. C., Llorente, S., Crespo, M., Rodriguez-Benot, A., de Gracia Guindo, M. D. C., Diaz-Corte, C., Gentil, M
|
2019
|
| The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study
|
Nozaki, A., Atsukawa, M., Kondo, C., Toyoda, H., Chuma, M., Nakamuta, M., Uojima, H., Takaguchi, K., Ikeda, H., Watanabe, T., Ogawa, S., Itokawa, N., Arai, T., Hiraoka, A., Asano, T., Fujioka, S., Ikegami, T., Shima, T., Ogawa, C., Akahane, T., Shimada, N., Fukunishi, S., Abe, H., Tsubota, A., Genda, T., Okubo, H., Mikami, S., Morishita, A., Moriya, A., Tani, J., Tachi, Y., Hotta, N., Ishikawa, T., Okanoue, T., Tanaka, Y., Kumada, T., Iwakiri, K., Maeda, S.
|
2020
|
| Outcomes After Direct-Acting Antiviral Therapy Based on Donor Hepatitis C Serostatus Among Hepatitis C Virus-Infected Kidney Transplant Recipients
|
Sedki, M., Cortesi, C., O'Brien, C., Levy, C., Martin, P., Roth, D., Bhamidimarri, K. R.
|
2020
|
| Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era
|
Devresse, A., Delire, B., Lazarus, J. V., Kabamba, B., De Meyer, M., Mourad, M., Buemi, A., Darius, T., Cambier, J. F., Goffin, E., Jadoul, M., Kanaan, N.
|
2020
|
| Changes in Office Blood Pressure Control, Augmentation Index, and Liver Steatosis in Kidney Transplant Patients after Successful Hepatitis C Infection Treatment with Direct Antiviral Agents
|
Kolonko, A., Musialik, J., Chudek, J., Bartmaska, M., Sabiak-Ba, N., Kujawa-Szewieczek, A., Kuczera, P., Kwiecie-Furmaczuk, K., Wicek, A.
|
2020
|
| Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitisC virus infection aged 75years
|
Kinoshita, A., Koike, K., Mizuno, Y., Ogata, I., Kobayashi, Y., Hasegawa, K., Shiraishi, K., Yoshida, H., Nakata, R., Yamada, N., Yasuda, K.
|
2020
|
| Combined NS5A & NS5B Nucleotide Inhibitor Therapy For Patients With Chronic Hepatitis C With Stage 5 Chronic Kidney Disease On Hemodialysis
|
Debnath, P., Chandnani, S., Rathi, P., Nair, S., Pawar, V., Contractor, Q.
|
2020
|
| Hepatitis C Treatment Of Renal Transplant And Chronic Kidney Disease Patients: Efficacy And Safety Of Direct-Acting Antiviral Regimens Containing Sofosbuvir
|
Michels, F. B. L., Amaral, A. C. C., Carvalho-Filho, R. J., Vieira, G. A., Souza, Alds, Ferraz, M. L. G.
|
2020
|
| Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
|
Puenpatom, A., Cao, Y., Yu, X., Kanwal, F., El-Serag, H. B., Kramer, J. R.
|
2020
|
| Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan
|
Mandhwani, R., Hanif, F. M., Lail, G., Luck, N. H., Khalid, M. A., Ul Haque, M. M., Laeeq, S. M., Aziz, T.
|
2020
|
| Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study
|
Darema, M., Cholongitas, E., Filiopoulos, V., Marinaki, S., Pavlopoulou, I. D., Tsoubou, I., Boletis, J. N., Papatheodoridis, G. V.
|
2020
|
| Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study
|
Feld, J. J., Cypel, M., Kumar, D., Dahari, H., Pinto Ribeiro, R. V., Marks, N., Kamkar, N., Bahinskaya, I., Onofrio, F. Q., Zahoor, M. A., Cerrochi, O., Tinckam, K., Kim, S. J., Schiff, J., Reichman, T. W., McDonald, M., Alba, C., Waddell, T. K., Sapisochin, G., Selzner, M., Keshavjee, S., Janssen, H. L. A., Hansen, B. E., Singer, L. G., Humar, A.
|
2020
|
| Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation
|
Gaur, N., Malhotra, V., Agrawal, D., Singh, S. K., Beniwal, P., Sharma, S., Jhorawat, R., Rathore, V., Joshi, H.
|
2020
|
| Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
|
Cheng, P. N., Chen, C. Y., Yu, M. L., Lin, C. C., Lin, C. Y., Peng, C. Y., Tseng, K. C., Lo, C. C., Tseng, I. H., Liu, C. J.
|
2020
|
| Sofosbuvir-Based HCV Treatment in Maintenance Hemodialysis Patients: A Single-Center Study
|
Gohel, K., Borasadia, P.
|
2020
|
| Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar)
|
Vacchi, C., Visentini, M., Gragnani, L., Fraticelli, P., Tavoni, A., Filippini, D., Saccardo, F., Lauletta, G., Colantuono, S., Atzeni, F., Pioltelli, P., Manfredi, A., Casato, M., Zignego, A. L., Monti, G., Pietrogrande, M., Galli, M., Sebastiani, M.
|
2020
|
| Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
|
Lawitz, E., Landis, C. S., Flamm, S. L., Bonacini, M., Ortiz-Lasanta, G., Huang, J., Zhang, J., Kirby, B. J., De-Oertel, S., Hyland, R. H., Osinusi, A. O., Brainard, D. M., Robson, R., Maliakkal, B. J., Gordon, S. C., Gane, E. J.
|
2020
|
| Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
|
Jang, E. S., Kim, K. A., Kim, Y. S., Kim, I. H., Lee, B. S., Lee, Y. J., Chung, W. J., Jeong, S. H.
|
2020
|
| Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience
|
Chevallier, E., Bchler, M., Caillard, S., Bouvier, N., Colosio, C., Rivalan, J., Sayegh, J., Bertrand, D., Le Meur, Y., Thierry, A., Garrouste, C., Rerolle, J. P., Rostaing, L., Gatault, P.
|
2020
|
| Interactive Impacts from Hepatitis C Virus Infection and Mixed Cryoglobulinemia on Complement Levels
|
Chang, M. L., Hu, J. H., Chen, W. T., Lin, M. S., Kuo, C. J., Chen, S. C., Chien, R. N.
|
2020
|
| Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
|
Yen, H. H., Su, P. Y., Zeng, Y. H., Liu, I. L., Huang, S. P., Hsu, Y. C., Chen, Y. Y., Yang, C. W., Wu, S. S., Chou, K. C.
|
2020
|
| Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses
|
Pozzato, G., Mazzaro, C., Artemova, M., Abdurakhmanov, D., Grassi, G., Crosato, I., Mauro, E., Ghersetti, M., Zorat, F., Bomben, R., Bulian, P., Gattei, V.
|
2020
|
| Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients
|
Torabi, J., Rocca, J. P., Ajaimy, M., Melvin, J., Campbell, A., Akalin, E., Liriano, L. E., Azzi, Y., Pynadath, C., Greenstein, S. M., Le, M., Goldstein, D. Y., Fox, A. S., Carrero, J., Weiss, J. M., Powell, T., Racine, A. D., Reinus, J. F., Kinkhabwala, M. M., Graham, J. A.
|
2020
|
| High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy
|
Chen, W. M., Wei, K. L., Tung, S. Y., Shen, C. H., Chang, T. S., Yen, C. W., Hsieh, Y. Y., Chiu, W. N., Hu, J. H., Lu, S. N., Hung, C. H.
|
2020
|
| Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
|
Park, Y. J., Woo, H. Y., Heo, J., Park, S. G., Hong, Y. M., Yoon, K. T., Kim, D. U., Kim, G. H., Kim, H. H., Song, G. A., Cho, M.
|
2020
|
| Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection
|
Sise, M. E., Goldberg, D. S., Kort, J. J., Schaubel, D. E., Alloway, R. R., Durand, C. M., Fontana, R. J., Brown, R. S., Jr., Friedewald, J. J., Prenner, S., Landis, J. R., Fernando, M., Phillips, C. C., Woodle, E. S., Rike-Shields, A., Sherman, K. E., Elias, N., Williams, W. W., Gustafson, J. L., Desai, N. M., Barnaba, B., Norman, S. P., Doshi, M., Sultan, S. T., Aull, M. J., Levitsky, J., Belshe, D. S., Chung, R. T., Reese, P. P.
|
2020
|
| Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
|
Yap, D. Y. H., Liu, K. S. H., Hsu, Y. C., Wong, G. L. H., Tsai, M. C., Chen, C. H., Hsu, C. S., Hui, Y. T., Li, M. K. K., Liu, C. H., Kan, Y. M., Yu, M. L., Yuen, M. F.
|
2020
|
| Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis
|
Shehadeh, F., Kalligeros, M., Byrd, K., Shemin, D., Mylonakis, E., Martin, P., D'Agata, E. M. C.
|
2020
|
| Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study
|
Durand, C. M., Barnaba, B., Yu, S., Brown, D. M., Chattergoon, M. A., Bair, N., Naqvi, F. F., Sulkowski, M., Segev, D. L., Desai, N. M.
|
2020
|
| Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors
|
Terrault, N. A., Burton, J., Ghobrial, M., Verna, E., Bayer, J., Klein, C., Victor, D., Mohan, S., Trotter, J., Dodge, J., Niemann, C. U., Rubin, R. A.
|
2020
|
| Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)
|
Stein, K., Stoehr, A., Klinker, H., Teuber, G., Naumann, U., John, C., Heyne, R., Serfert, Y., Niederau, C., Zeuzem, S., Berg, T., Wiegand, J.
|
2020
|
| Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance hemodialysis
|
Taneja, S., Duseja, A., Mehta, M., De, A., Verma, N., Premkumar, M., Dhiman, R. K., Singh, V., Singh, M. P., Ratho, R. K., Ramachandran, R., Kumar, V., Kohli, H. S.
|
2020
|
| Clinico-immunologic outcomes of HCV-cured cryoglobulinemia: lower relapse rate with interferon-based than interferon-free therapy
|
Colantuono, S., Marrapodi, R., Del Padre, M., Collalti, G., Garzi, G., De Santis, A., Fiorilli, M., Basili, S., Visentini, M., Casato, M.
|
2020
|
| Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience
|
Abd-Elsalam, S., Abo-Amer, Y. E., El-Abgeegy, M., Elshweikh, S. A., Elsergany, H. F., Ahmed, R., Elkadeem, M., Hawash, N., Soliman, S., Badawi, R., Elguindy, A. M. A., Soliman, M. Y., Mohmed, A. A., Mansour, L.
|
2020
|
| Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis
|
Xu, H. Q., Wang, C. G., Xiao, P., Gao, Y. H.
|
2020
|
| Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality
|
Goetsch, M. R., Tamhane, A., Overton, E. T., Towns, G. C., Franco, R. A.
|
2020
|
| Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir
|
Goel, A., Bhadauria, D. S., Kaul, A., Verma, A., Tiwari, P., Rungta, S., Rai, P., Gupta, A., Aggarwal, R.
|
2020
|
| The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients
|
Yazawa, M., Flp, T., Cseprekal, O., Talwar, M., Balaraman, V., Bhalla, A., Azhar, A., Kovesdy, C. P., Eason, J. D., Molnar, M. Z.
|
2020
|
| The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease
|
Elmowafy, A. Y., Abbas, M. H., Denewar, A. A., Mashaly, M. E., Shiha, G., El Wasif, S. M., Rostaing, L., Bakr, M. A.
|
2020
|
| Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment
|
Cheng, T. S., Liang, P. C., Huang, C. F., Yeh, M. L., Huang, C. I., Lin, Z. Y., Chen, S. C., Huang, J. F., Dai, C. Y., Hsieh, P. H., Chuang, W. L., Yu, M. L.
|
2020
|
| The Psychosocial Burden of HCV Infection and the Impact of Antiviral Therapy on the Quality of Life in Liver and Kidney Transplant Recipients: A Pilot Study
|
Santonicola, A., Bilancio, G., Zingone, F., Donnarumma, L., Caputo, C., Ciacci, C.
|
2020
|
| Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis
|
Salim, A., Farooq, M. O., Mengal, F. U. A., Malik, K.
|
2020
|
| DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5
|
Dai, C. Y., Huang, J. F., Chuang, W. L., Yu, M. L.
|
2020
|
| Hepatitis C positive donor to negative recipient kidney transplantation: A real world experience
|
Jandovitz, N., Nair, V., Grodstein, E., Molmenti, E., Fahmy, A., Abate, M., Bhaskaran, M., Teperman, L.
|
2020
|
| Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience
|
Alkadi, M. M., Abuhelaiqa, E. A., Elshirbeny, M. F., Hamdi, A. F., Fituri, O. M., Asim, M., Alkaabi, S. R., Derbala, M. F., Jarman, M. E., Ashour, A. M., Nauman, A., Al Maslamani, Y. K., Butt, A. A., Al-Malki, H. A.
|
2020
|
| Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial
|
Ferri, C., Marzo, E., Longombardo, G., Lombardini, F., La Civita, L., Vanacore, R., Liberati, A. M., Gerli, R., Greco, F., Moretti, A., et al.
|
1993
|
| Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial
|
Ferri, C., Marzo, E., Longombardo, G., La Civita, L., Lombardini, F., Giuggioli, D., Vanacore, R., Liberati, A. M., Mazzoni, A., Greco, F.
|
1993
|
| Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
|
Misiani, R., Bellavita, P., Fenili, D., Vicari, O., Marchesi, D., Sironi, P. L., Zilio, P., Vernocchi, A., Massazza, M., Vendramin, G.
|
1994
|
| Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study
|
Dammacco, F., Sansonno, D., Han, J. H., Shyamala, V., Cornacchiulo, V., Iacobelli, A. R., Lauletta, G., Rizzi, R.
|
1994
|
| Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia
|
Mazzaro, C., Lacchin, T., Moretti, M., Tulissi, P., Manazzone, O., Colle, R., Pozzato, G.
|
1995
|
| Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia
|
Adinolfi, L. E., Utili, R., Zampino, R., Ragone, E., Mormone, G., Ruggiero, G.
|
1997
|
| Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon
|
Frangeul, L., Cresta, P., Perrin, M., Duverlie, G., Khorsi, H., Musset, L., Opolon, P., Huraux, J. M., Lunel, F.
|
1998
|
| Long-term results regarding the interferon alpha-2b in the treatment essential cryoglobulinemia
|
Lauta, V. M., De, S. A.
|
1995
|
| Interferon-alpha in mixed cryoglobulinaemia patients: a randomized, crossover-controlled trial
|
Penny, R.
|
1993
|
| Interferon alfa VS steroids in patients with HCV cryoglobulinemic glomerulonephritis
|
Mazzaro, C., Panarello, G., Faelli, A., Donada, C., Baracetti, S., Zorat, F., Nascimben, F., Pozzato, G.
|
1999
|
| Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C
|
Huraib, S., Iqbal, A., Tanimu, D., Abdullah, A.
|
2001
|
| Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia
|
Joshi, S., Kuczynski, M., Heathcote, E. J.
|
2007
|
| Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia
|
Stefanutti, C., Vivenzio, A., Di Giacomo, S., Labbadia, G., Mazza, F., D'Alessandri, G., Ferraro, P. M., Masala, C.
|
2009
|
| Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study
|
Dammacco, F., Tucci, F. A., Lauletta, G., Gatti, P., De Re, V., Conteduca, V., Sansonno, S., Russi, S., Mariggi, M. A., Chironna, M., et al.
|
2010
|
| A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis
|
De Vita, S., Quartuccio, L., Isola, M., Mazzaro, C., Scaini, P., Lenzi, M., Campanini, M., Naclerio, C., Tavoni, A., Pietrogrande, M., et al.
|
2012
|
| Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study
|
Gragnani, L., Fabbrizzi, A., Triboli, E., Urraro, T., Boldrini, B., Fognani, E., Piluso, A., Caini, P., Ranieri, J., Monti, M., et al.
|
2014
|
| Rituximab monotherapy of severe HCV-related cryoglobulinemic vasculitis for more than 2 years: follow-up of a randomized controlled multicentre study
|
Quartuccio, L., Zuliani, F., Corazza, L., Scaini, P., Zani, R., Lenzi, M., Tavoni, A., Sebastiani, M., Baldovino, S., Urraro, T., et al.
|
2014
|
| A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome
|
De Vita, S., Quartuccio, L., Isola, M., Masolini, P., Sacco, S., De Marchi, G., Mazzaro, C.
|
2010
|
| PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-Associated mixed cryoglobulinemia vasculitis
|
Saadoun, D., Resche Rigon, M., Pol, S., Thibault, V., Blanc, F., Pialoux, G., Karras, A., Bazin-Kara, D., Cazorla, C., Vittecoq, D., et al.
|
2015
|
| Sirolimus conversion may suppress viral replication in hepatitis C virus-positive renal transplant candidates
|
Soliman, A., Fathy, A., Khashab, S., Shaheen, N., Soliman, M.
|
2013
|
| Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
|
Desnoyer, A., Pospai, D., Le, M. P., Gervais, A., Heurgue-Berlot, A., Laradi, A., Harent, S., Pinto, A., Salmon, D., Hillaire, S., et al.
|
2016
|
| C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis c virus genotype 1 infection and chronic kidney disease
|
Bruchfeld, A., Roth, D., Nelson, D., Liapakis, A. M., Silva, M., Monsour, H., Martin, P., Pol, S., Londono, M. C., Hassanein, T., et al.
|
2015
|
| Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study
|
Kawakami, Y., Imamura, M., Ikeda, H., Suzuki, M., Arataki, K., Moriishi, M., Mori, N., Kokoroishi, K., Katamura, Y., Ezaki, T., et al.
|
2016
|
| Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection in patients with renal dysfunction; From real world data
|
Ishigami, M., Hayashi, K., Honda, T., Kuzuya, T., Ishizu, Y., Hirooka, Y., Goto, H.
|
2016
|
| RUBY-II: efficacy and safety of a ribavirin-free ombitasvir/ paritaprevir/ritonavir +/- dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV Genotypes 1a or 4 infection
|
Gane, E. J., Sola, R., Cohen, E., Roberts, S. K., George, J., Skoien, R., Riordan, S., Mobashery, N., Abunimeh, M., Cohen, D. E., et al.
|
2016
|
| RUBY-I: safety and efficacy of ombitasvir/paritaprevir/ ritonavir and dasabuvir with or without ribavirin in adults with genotype 1 chronic hepatitis C Virus (HCV) infection with severe renal impairment or end-stage renal disease
|
Vierling, J. M., Lawitz, E., Reddy, K. R., Cohen, E., Kemmer, N., Morelli, G., Zamor, P. J., Bennett, M., Bernstein, D. E., Kowdley, K. V., et al.
|
2016
|
| Ledipasvir/sofosbuvir is effective and well tolerated in post-kidney transplant patients with chronic hepatitis C virus
|
Morales, A., Liriano-Ward, L. E., Tierney, A., Sang, M., Lalos, A., Hassan, M. A., Nair, V., Schiano, T., Smith, C., Satoskar, R.
|
2016
|
| A prospective, multicenter study of daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection on hemodialysis
|
Sung, J., Uojima, H., Ohtake, T., Kinbara, T., Oka, M., Matsumoto, S., Kobayashi, S., Kako, M.
|
2016
|
| Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 study
|
Barr, E., Roth, D., Bruchfeld, A., Martin, P., Nelson, D. R., Silva, M., Monsour, H., Alric, L., Wan, S., Jackson, B., et al.
|
2016
|
| Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 hcv infection
|
Colombo, M., Aghemo, A., Liu, L., Hyland, R., Yun, C., Brainard, D., McHutchison, J., Bourliere, M., Peck-Radosavljevic, M., Manns, M., et al.
|
2016
|
| Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: preliminary Results From a Multicenter Study
|
Gentil, M. A., Gonzalez-Corvillo, C., Perello, M., Zarraga, S., Jimenez-Martin, C., Lauzurica, L. R., Alonso, A., Franco, A., Hernandez-Marrero, D., Sanchez-Fructuoso, A.
|
2016
|
| Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction
|
Ishigami, M., Hayashi, K., Honda, T., Kuzuya, T., Ishizu, Y., Ishikawa, T., Nakano, I., Urano, F., Kumada, T., Yoshioka, K., et al.
|
2017
|
| Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: a Post-Hoc Analysis of Phase 3 Clinical Trials
|
Mehta, D. A., Cohen, E., Charafeddine, M., Cohen, D. E., Bao, Y., Sanchez Gonzalez, Y., Tran, T. T.
|
2017
|
| Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients with renal insufficiency in the German Hepatitis CRegistry
|
Hinrichsen, H., Wiegand, J., Schott, E., Buggisch, P., Gerken, G., Heyne, R., Lutz, T., Ullrich, R., Konig, B., Hettinger, J.
|
2016
|
| Efficacy and safety profile of direct-acting antiviral agents in hemodialysis patients with chronic hepatitis C infection
|
Hanif, F., Luck, N., Mandhwani, R.
|
2017
|
| Ombitasvir, paritaprevir, and ritonavir for treatment of chronic hepatitis C hemodialysis dependent patients
|
Elmowafy, A. Y., Elmaghrabi, H. M., Zahab, M. A., Eldahshan, K. F., Soliman, R., Elbasiony, M., Mashaly, M. E., Matter, Y. E., Elwasif, S. M., Donia, A. F., et al.
|
2018
|
| Impact of direct antiviral agents on health-related quality of life in patients of chronic hepatitis C with chronic kidney disease
|
Duseja, A., Tiwari, P., Ramachandran, R.
|
2018
|
| Effectiveness of ombitasvir/paritaprevir/ritonavir-dasabuvir-ribavirin in hemodialysis patients with chronic HCV
|
Yildiz, O., Aygen, B., Gokahmetoglu, S., Baltaci, S., Mumcu, N., Eren, E.
|
2018
|
| Treatment uptake and real world effectiveness of sofosbuvir/ ledipasvir and paritaprevir/ritonavir/ombitasvir/dasabuvir among HCV-infected persons with chronic kidney disease
|
Alkadi, M. M., Ren, Y., Puenpatom, A., Kumar, R., Arduino, J. M., Abou-Samra, A. B., Butt, A. A.
|
2017
|
| Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: retrospective data analyses from the TRIO Network
|
Bacon, B., Curry, M., Dieterich, D., Flamm, S., Kowdley, K., Milligan, S., Nwankwo, C., Tsai, N., Younossi, Z., Afdhal, N.
|
2017
|
| 100% efficacy to ombitasvir/paritaprevir/ritonavir ( dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patients
|
Sanai, F. M., Alghamdi, A. S., Afghani, A., Alswat, K. A., Aseeri, A., Babatin, M. A.
|
2017
|
| HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
|
Nct
|
2016
|
| Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
|
Nct
|
2001
|
| Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
|
Nct
|
2005
|
| Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trial
|
Basu, P. P., Shah, N. J., Ashfique, Farhat, S., Siriki, R.
|
2014
|
| Adherence to pangenotypic glecaprevir/pibrentasvir treatment and SVR12 in HCVinfected patients: an integrated analysis of the phase 2/3 clinical trial program
|
Brown, A
|
2017
|
| A pragmatic approach to optimizing the efficacy of elbasvir/grazoprevir using baseline viral load in participants with hepatitis C virus (HCV) genotype (GT)1a infection: a post hoc analysis of 11 clinical trials
|
Serfaty, L, Jacobson, I, Rockstoh, J
|
2017
|
| Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis
|
Gragnani, L., Cerretelli, G., Lorini, S., Steidl, C., Giovannelli, A., Monti, M., Petraccia, L., Sadalla, S., Urraro, T., Caini, P., et al.
|
2018
|
| Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
|
Bruchfeld, A., Roth, D., Martin, P., Nelson, D. R., Pol, S., Londoo, M. C., Monsour, H., Silva, M., Hwang, P., Arduino, J. M., et al.
|
2017
|
| A randomized open-label trial of paritaprevir plus ritonavir plus ombitasvir in the treatment of HCV genotype 4-infected patients with stage 4-5 chronic kidney disease
|
Sanai, F., Babatin, M., Khan, M. Q., Alghamdi, H. S., Alswat, K. A., Aleid, H., Alqahtani, A., Albiladi, H., Alghamdi, A. S., Batwa, F. A., et al.
|
2018
|
| Sofosbuvir with NS5A inhibitors in hepatitis C virus (HCV) infected renal transplant recipients
|
Singh, A., Kumari, S., Leishangthem, B., Singh, V.
|
2018
|
| Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir +/- ribavirin
|
Tran, T.T.
|
2017
|
| Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trial
|
Basu, P., Shah, N., Siriki, R., Rahaman, M., Farhat, S.
|
2013
|
| Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population
|
Basu, P., Sinki, R., Shah, N., Farhat, S., Mittimani, K., Atluri, S.
|
2013
|
| Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C
|
Mousa, D. H., Abdalla, A. H., Al-Shoail, G., Al-Sulaiman, M. H., Al-Hawas, F. A., Al-Khader, A. A.
|
2004
|
| Ledipasvir/sofosbuvir (LDV/SOF) for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection
|
Pol, S., Aghemo, A., Lin, L., Hyland, R., Yun, C., Spellman, J., Natha, M., Brainard, D., McHutchison, J., Bourliere, M., et al.
|
2016
|
| A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects With Renal Insufficiency
|
Drks
|
2020 (2014 protocol)
|
| Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisC
|
Jprn, Umin
|
2010
|
| Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure
|
Jprn, Umin
|
2013
|
| Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis C
|
Jprn, Umin
|
2014
|
| A randomized, open label, multicenter, parallel group study evaluating the efficacy and safety of 135 mcg and 90 mcg of Pegasys given as monotherapy to patients with chronic hepatitis C and end-stage renal disease undergoing hemodialysis
|
Euctr, I. T.
|
2007
|
| A prospective multicenter study for characterization of renal function G1b CHC patients with CKD-3 treated with elbasvir plus grazoprevir
|
Jprn, Umin
|
2017
|
| The efficacy of paritaprevir and ombitasvir with a booster dose of ritonavir in genotype 1 HCV patients with hemodialysis
|
Jprn, Umin
|
2016
|
| Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
|
Jprn, Umin
|
2016
|
| Anti-CD20 monoclonal antibody therapy for type II mixed cryoglobulinemia syndrome
|
Isrctn
|
2012
|
| A multicenter phase II study assessed safety and efficacy of asunaprevir and daclatasvir in patients with chronic hepatitis C virus genotype 1 infection and end-stage renal disease requiring hemodialysis
|
Jprn, Umin
|
2017 (2014 protocol)
|
| Efficacy and safety of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysis
|
Jprn, Umin
|
2017 (2015 protocol)
|
| Predictive factors associated with virological response in Daclatasvir and Asunaprevir combination therapy for genotype1b-infected chronic hepatitis C patients : multicenter study
|
Jprn, Umin
|
2015
|
| Antiviral therapy for HCV using direct acting antiviral drugs in patients with chronic hepatitis C undergoing hemodialysis
|
Jprn, Umin
|
2015
|
| Evaluation of HCV clearance by hemodialysis
|
Euctr, A. T.
|
2009
|
| Efficacy and safety of Ledipasvir/Sofosbuvir in chronic hepatitis C of Genotype1b with chronic kidney disease(eGFR30-60ml/min/1.73m2)
|
Jprn, Umin
|
2017
|
| Efficacy and safety of glecaprevir and pibrentasvir in chronic hepatitis C patients with hemodialysis
|
Jprn, Umin
|
2017
|
| Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by glecaprevir and pibrentasvir therapy in HCV-infected hemodialysis patients
|
Jprn, Umin
|
2018
|
| Safety and efficacy of Glecaprevir / Pibrentasvir combination therapy for chronic hepatitis C - including hemodialysis patients
|
Jprn, Umin
|
2018
|
| Elbasvir/Grazoprevir (EBR/GZR) treatment of Hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study
|
Bruchfeld, A., Roth, D., Martin, P., Nelson, D., Stanislas, P., Londono, M. C., Viviani, D., Wan, S., Arduino, J., Robertson, M., et al.
|
2016
|
| Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis
|
Irct20170614034526N
|
2019
|
| Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
|
Nct
|
2002
|
| Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Nave Hemodialysis Patients With Chronic Hepatitis C
|
Nct
|
2007
|
| Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
|
Nct
|
2014
|
| SofosbuvirVelpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation
|
Gaur, N., Malhotra, V., Agrawal, D., Singh, S. K., Beniwal, P., Sharma, S., Jhorawat, R., Rathore, V., Joshi, H.
|
2019
|
| Outcomes of patients with hcv-associated cryoglobulinemia after ifn-free therapy: a monocenter retrospective study
|
Zuglian, G., Odolini, S., Carriero, C., Chirico, C., Marchese, V., Nasta, P., Zaltron, S., Spinetti, A., Castelli, F.
|
2019
|
| Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
|
Lawitz, E., Landis, C. S., Flamm, S. L., Bonacini, M., Ortiz-Lasanta, G., Huang, J., Zhang, J., Kirby, B. J., De-Oertel, S., Hyland, R. H., et al.
|
2020
|
| Interactions between immunosuppressive therapy and direct-acting antivirals in kidney transplant recipient with hepatitis C infection
|
Carta, P., Curci, F., Caroti, L., Aida, L., Di Maria, L., Cirami, L.
|
2020
|
| Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection
|
Lawitz, E., Flisiak, R., Abunimeh, M., Sise, M. E., Park, J. Y., Kaskas, M., Bruchfeld, A., Worns, M. A., Aglitti, A., Zamor, P. J., et al.
|
2020
|
| Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease
|
Gane, E., Poordad, F., Zadeikis, N., Valdes, J., Lin, C. W., Liu, W., Asatryan, A., Wang, S., Stedman, C., Greenbloom, S., et al.
|
2019
|
| Long-term follow-up of cryoglobulinemic syndrome with renal involvement after daa
|
Affatato, S., Pollastri, E., Belotti, E., Zani, R., Zaltron, S., Spinetti, A., Castelli, F., Scolari, F.
|
2020
|
| Detection of Hepatitis C Antibodies Without Viral Transmission in Hepatitis C-Negative Recipients Receiving Kidneys From Hepatitis C-Positive Donors Treated With Direct-Acting Antiviral Therapy
|
Agarwal, N., Davis, R. J., Gracey, D. M., Wong, G., Kable, K., Wong, J. K. W., Nankivell, B. J., Strasser, S., Wyburn, K.
|
2018
|
| Superiority of peginterferon -2a and ribavirin combination over peginterferon -2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection
|
Al-Ghamdi, S. M. G., Alaulaqi, N., Al-Amoudi, A. A., Alghamdi, A., Zagnoon, A., Sadiq, B. B.
|
2017
|
| Pretreatment circulating cryoglobulin predicts improvement in patient reported fatigue during directing acting antiviral therapy for chronic hepatitis c infection
|
Al-Jashaami, L., Abidali, H., Patel, A., Choi, M., Pedersen, M., Seetharam, A. B.
|
2017
|
| Persistent hepatitis C virusassociated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy
|
Artemova, M., Abdurakhmanov, D., Ignatova, T., Mukhin, N.
|
2017
|
| Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trial
|
Basu, P., Siriki, R., Shah, N. J., Farhat, S., Mittimani, K., Atluri, S.
|
2013
|
| Cryoglobulin mediated kidney disease: HCV infection, histological patterns, role of rituximab. monocentric report
|
Cerami, C., Scichilone, L. M., Mascia, M. T., Campioli, D., Cappelli, G.
|
2018
|
| Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir
|
Chia, X. X., Cherepanoff, S., Danta, M., Furlong, T.
|
2018
|
| The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection
|
El-Serag, H. B., Christie, I. C., Puenpatom, A., Castillo, D., Kanwal, F., Kramer, J. R.
|
2019
|
| HCV-infected solid organ donors, direct-acting antivirals and the current challenges
|
Fabrizi, F., Cerutti, R., Silva, M.
|
2020
|
| Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study
|
Franco, A., Moreso, F., Merino, E., Sancho, A., Kanter, J., Gimeno, A., Balibrea, N., Rodriguez, M., Perez Contreras, F.
|
2019
|
| Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation
|
Giannelli, F., Moscarella, S., Giannini, C., Caini, P., Monti, M., Gragnani, L., Romanelli, R. G., Solazzo, V., Laffi, G., La Villa, G., et al.
|
2003
|
| Biomarkers of minimal residual disease in rituximab treated patients with mixed cryoglobulinemia
|
Gulli, F., Marino, M., Napodano, C., Pocino, K., Basile, V., Marrapodi, R., Colantuono, S., Rapaccini, G. L., Visentini, M., Basile, U.
|
2019
|
| Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience
|
Hassan, A. M., Osman, H. A., Mahmoud, H. S., Hassan, M. H., Hashim, A. A., Ameen, H. H.
|
2018
|
| Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection
|
Hogan, J. J., Lim, M. A., Palmer, M. B., Bloom, R. D., Chung, R. T., Sise, M. E.
|
2017
|
| Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin
|
Kapila, N., Flocco, G., Al Khalloufi, K., Zervos, X. B.
|
2019
|
| Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus
|
Kogiso, T., Sagawa, T., Kodama, K., Taniai, M., Katagiri, S., Egawa, H., Yamamoto, M., Tokushige, K.
|
2019
|
| A pilot study in comparing the efficacy and safety of peginterferon alfa-2a and interferon alfa-2a in treating patients with end stage renal disease and chronic hepatitis C
|
Liu, C. H.
|
2005
|
| Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu, C. H., Peng, C. Y., Fang, Y. J., Kao, W. Y., Yang, S. S., Lin, C. K., Lai, H. C., Su, W. P., Fang, S. U., Chang, C. C., Su, T. H., Liu, C. J., Chen, P. J., Chen, D. S., Kao, J. H.
|
2020
|
| Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia
|
Miailhes, P., Hartig-Lavie, K., Virlogeux, V., Pradat, P., Diakite, M., Uhres, A. C., Zoulim, F., Sarda, M. N.
|
2018
|
| Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials
|
Nangia, G., Vierling, J. M., Kwo, P., Brown, D. D., Klopfer, S. O., Robertson, M. N., Haber, B. A., Reddy, K. R.
|
2020
|
| Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection
|
Nct
|
2014
|
| Real-world use of elbasvir/grazoprevir and outcomes in patients with Chronic Hepatitis C: retrospective data analyses from the TRIO Network
|
Nwankwo, C., Bacon, B., Curry, M., Dieterich, D., Flamm, S., Milligan, S., Tsai, N., Younossi, Z., Afdhal, N.
|
2018
|
| Regression of hepatitis C virus-associated membranoproliferative glomerulonephritis with direct-acting antiviral therapy after liver transplantation
|
Okamura, K., Kuwabara, T., Enoki, H., Kohda, Y., Adachi, M., Hayashida, S., Inomata, Y., Mukoyama, M.
|
2019
|
| Interventions for dialysis patients with hepatitis C virus (HCV) infection
|
Prabhu, R. A., Nair, S., Pai, G., Reddy, N. P., Suvarna, D.
|
2015
|
| Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations
|
Rossi, C., Jeong, D., Wong, S., McKee, G., Butt, Z. A., Buxton, J., Wong, J., Darvishian, M., Bartlett, S., Samji, H., Yu, A., Binka, M., Alvarez, M., Adu, P. A., Tyndall, M., Krajden, M., Janjua, N. Z.
|
2019
|
| Efficacy of l-carnitine on the ribavirin induced hemolytic anemia for patients with HCV infection
|
Sato, S.
|
2018
|
| The effect of interferon-free direct-acting antivirals therapy on hepatitis C virus infected patients with Cryoglobulinemia
|
Terashita, K., Takagi, T., Miyagishima, T., Matsuda, S., Suda, G., Sakamoto, N.
|
2019
|
| Fixed-dose combination of sofosbuvir and ledipasvir in the treatment of hepatitis C infection in patients on hemodialysis: Report of an initial experience
|
Vikrant, S., Jaryal, A.
|
2018
|
| Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease
|
Vionnet, J., Saouli, A. C., Pascual, M., Stucker, F., Decosterd, L. A., Moradpour, D., Chtioui, H.
|
2016
|
| Efficacy and safety of direct-acting antiviral-based treatment in hepatitis C virus infected patients with chronic renal function impairment: An updated systemic review and meta-analysis
|
Yang, H., Hu, X., Pu, L., Ren, S., Feng, Y.
|
2020
|
| Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study
|
Uojima, H.
|
2017
|
| First year renal outcome of transplantations of kidneys from hepatitis c infected donors to hepatitis c negative recipients
|
Molnar, M.Z., et al.
|
2020
|
| Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease
|
Chuang, W-L, Hu, Tsung-Hui, Buggisch, Peter , Moreno, Christophe , Su, Wei-Wen, Biancone, Luigi, Camargo, Marianne, Hyland, Robert, Lu, Sophia, Kirby, Brian J., Dvory-Sobol, Hadas, Osinusi, Anu, Gaggar, Anuj, Peng, Cheng-Yuan, Liu, Chen-Hua, Sise, Meghan E., Mangia, Alessandra
|
2021
|
| Impact of hepatitis c virus and direct acting antivirals on Japanese renal allograft recipients
|
Okino, K., et al.
|
2020
|
| Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.
|
Bhamidimarri, Kalyan Ram, Czul, Frank, Peyton, Adam, Levy, Cynthia, Hernandez, Maria, Jeffers, Lennox, Roth, David, Schiff, Eugene, O'Brien, Christopher, Martin, Paul
|
2015
|
| New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
|
Mawatari, Seiichi, Oda, Kohei, Tabu, Kazuaki, Ijuin, Sho, Kumagai, Kotaro, Inada, Yukiko, Uto, Hirofumi, Hiramine, Yasunari, Kure, Takeshi, Fujisaki, Kunio, Hashiguchi, Masafumi, Hori, Takeshi, Oshige, Akihiko, Imanaka, Dai, Saishoji, Akiko, Taniyama, Oki, Sakae, Haruka, Tamai, Tsutomu, Moriuchi, Akihiro, Ido, Akio
|
2017
|
| Efficacy and safety of sofosbuvir and velpatasvir in renal transplant recipients with chronic hepatitis c virus infection
|
Greco R, et al.
|
2019
|
| Treatment of chronic viral hepatitis "C" with sofosbuvir-ledipasvir in patients with dialysis-dependent chronic kidney disease
|
Asanbek kyzy, A
|
2019
|
| Egyptian Experience of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
|
El-Raey, F, Mansour H, El-Gendy, N, Hegazy, M, Zaky, S
|
2019
|
| Hepatitis C virus can be eliminated from a prevalent kidney transplant recipient population: a single-centre study in the direct-acting antivirals era
|
Devresse A, et al.
|
2019
|
| HCV infection in nephrology: screening and management in nephropathic outpatients. A 36 months experience
|
Gernone G, et al.
|
2019
|
| Better blood pressure control in hcv-infected kidney transplant recipients after effective treatment with direct antiviral agents
|
Kolonko A, et al,
|
2019
|
| Direct acting antivirals are effective and safe in HCV positive kidney transplant recipients (KTRs), even with advanced liver fibrosis
|
Paoletti E, et al.
|
2019
|
| Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases-EpiTer-2 database analysis
|
Tomasiewicz K, et al.
|
2019
|
| Prospective multicenter study of sofosbuvir-velpatasvir (SOF/VEL) in hepatitis C virus (HCV) negative liver (LT) and kidney transplant (KT) recipients receiving HCV viremic donors
|
Rubin R, et al.
|
2020
|
| An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantation
|
Lee T-Y, et al.
|
2020
|
| Kidney transplant from hepatitis C positive donors to hepatitis C negative recipients: report on the first experience in the UK
|
Healy B, et al.
|
2020
|
| Grazoprevir/elbasvir for treatment of hepatitis C virus genotype 4 post kidney transplant
|
Abaalkhail F, et al.
|
2020
|
| Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - data from the German hepatitis C-registry (DHC-R)
|
Stein K, et al.
|
2020
|
| Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir
|
Telep L, et al.
|
2020
|
| Direct Acting Antiviral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C-Negative Kidney Transplant Recipients
|
Yakubu I, et al.
|
2020
|
| Transplantation of Kidneys from Hepatitis C-Infected Donors to Hepatitis C-Negative Recipients: 1-Year Renal Allograft Outcomes
|
Molnar, MZ, et al.
|
2020
|
| Hepatitis C NAT-Positive Kidney Transplant into Hepatitis C-Negative Recipients: A Single-Center Experience
|
Kaur T, et al.
|
2020
|
| Experience with Directly Acting Antiviral Agents for Hepatitis C in Maintenance Hemodialysis Patients in a Single Center from Pakistan
|
Rashid RM, et al.
|
2019
|
| Preemptive treatment with grazoprevir and elbasvir for donor hcv viremic donors to hcv negative recipient kidney transplantation
|
Sise M, et al.
|
2019
|
| Directly acting anti-viral agents improve health related quality of life in chronic hepatitis c patients with chronic kidney disease
|
Singhal R, et al.
|
2019
|
| Hepatitis C viremic organs transplanted into nonviremic recipients; a real world nurse practitioner led clinic
|
Parkinson E, et al.
|
2020
|
| 8 weeks versus 12 weeks of direct-acting antiviral therapy for kidney transplant recipients with chronic hepatitis C infection
|
Cioffi J, et al.
|
2020
|
| Comedications and their potential drug-drug interactions with direct-acting antiviral agents in hepatitis C patients on hemodialysis
|
Hsu P-Y, et al.
|
2020
|
| Establishment of an outreach, grouping health care system with sofosbuvir/velpatasvir to achieve micro-elimination of HCV in hemodialysis centers (ERASE-C)
|
Yu M-L, et al.
|
2020
|
| Long-term post-operative outcomes, waitlist times, and treatment results of hepatitis c negative liver, kidney, and simultaneous liver-kidney transplant recipients with hepatitis C positive donors
|
Ray J, et al.
|
2020
|
| Treatment efficacy and safety of sofosbuvir with velpatasvir for chronic hepatitis C among uremic patients under maintenance hemodialysis-an interim report of ERASE-C
|
Yu M-L, et al.
|
2020
|
| Treatment efficacy and safety of sofosbuvir/velpatasvir for chronic hepatitis C among uremic patients under maintenance hemodialysis-an interim report of ERASE-C
|
Yu M-L, et al.
|
2020
|
| Sofosbuvir plus Velpatasvir combination is safe and effective in treating chronic hepatitis C in patients with end stage renal disease (ESRD).
|
Duseja, A., et al.
|
2020
|
| Assessment of liver fibrosis using APRI score after treatment with elbasvir/grazoprevir in patients with hepatitis C infection and chronic kidney disease on hemodialysis
|
Bayu, L, et al.
|
2020
|
| Changes of liver fibrosis in chronic hepatitis C patients with chronic kidney disease who had undergone hemodialysis after DAA therapy
|
Suryamin M, et al.
|
2020
|
| Sofosbuvir/Velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis
|
Borgia SM, et al.
|
2019
|
| Use of Glecaprevir/Pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
|
Yap D Y-H, et al.
|
2019
|
| Elbasvir (EBR)/grazoprevir (GZR) is effective and tolerable for the treatment of HCV GT1-infected patients: a real world multicenter observatory study in Taiwan
|
Liu C-J, et al.
|
2020
|
| Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study
|
Pérez de José, A, Carbayo, J, Pocurull, A, Bada-Bosch, T, Cases Corona, CM, Shabaka, A, Ramos Terrada, N, Martinez Valenzuela, L, Huerta, A, Fernandez Lorente, L, Gelen Malek-Marín, T, Goicoechea, M
|
2021
|
| Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome.
|
Nowak Knut Michael, Witzke Oliver, Sotiropoulos Georgios C, Benkö Tamas, Fiedler Melanie, Timm Jörg, Kribben Andreas, Wilde Benjamin, Saner Fuat, Paul Andreas, Treckmann Jürgen
|
2017
|
| Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?
|
Trotter Patrick B, Summers Dominic M, Ushiro-Lumb Ines, Robb Matthew, Bradley J Andrew, Powell James, Watson Christopher J E, Neuberger James
|
2018
|
| Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.
|
Sageshima Junichiro, Troppmann Christoph, McVicar John P, Santhanakrishnan Chandrasekar, de Mattos Angelo M, Perez Richard V
|
2018
|
| Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.
|
Gupta Gaurav, Kang Le, Yu Jonathan W, Limkemann Ashley J, Garcia Victoria, Bandyopadhyay Dipankar, Kumar Dhiren, Fattah Hasan, Levy Marlon, Cotterell Adrian H, Sharma Amit, Bhati Chandra, Reichman Trevor, King Anne L, Sterling Richard
|
2017
|
| Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.
|
La Hoz Ricardo M, Sandıkçı Burhaneddin, Ariyamuthu Venkatesh K, Tanriover Bekir
|
2019
|
| Effect of Recipient Hepatitis C Status on Outcomes of Deceased Donor Kidney Transplantation.
|
Yuan Qing, Hong Shanjuan, Perez-Ortiz Andric, Roth Eve, Chang David C, Madsen Joren C, Elias Nahel
|
2020
|
| Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.
|
Sise Meghan E, Strohbehn Ian A, Chute Donald F, Gustafson Jenna, Van Deerlin Vivianna M, Smith Jennifer R, Gentile Caren, Wojciechowski David, Williams Winfred W, Elias Nahel, Chung Raymond T
|
2020
|
| Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
|
Friebus-Kardash Justa, Gäckler Anja, Kribben Andreas, Witzke Oliver, Wedemeyer Heiner, Treckmann Jürgen, Herzer Kerstin, Eisenberger Ute
|
2019
|
| Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site.
|
Van Pilsum Rasmussen Sarah E, Seaman Shanti, Brown Diane, Desai Niraj, Sulkowski Mark, Segev Dorry L, Durand Christine M, Sugarman Jeremy
|
2020 Jan-Mar
|
| Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.
|
Bowring Mary G, Shaffer Ashton A, Massie Allan B, Cameron Andrew, Desai Niraj, Sulkowski Mark, Garonzik-Wang Jacqueline, Segev Dorry L
|
2019
|
| Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation.
|
Sise Meghan E, Wojciechowski David, Chute Donald F, Gustafson Jenna, Chung Raymond T, Williams Winfred W, Elias Nahel
|
2019
|
| Treatment of hepatitis C-virus-related glomerulonephritis.
|
Kamar N, Rostaing L, Alric L
|
2006
|
| Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.
|
Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L
|
2006
|
| Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
|
Zaja Francesco, De Vita Salvatore, Mazzaro Cesare, Sacco Stefania, Damiani Daniela, De Marchi Ginevra, Michelutti Angela, Baccarani Michele, Fanin Renato, Ferraccioli Gianfranco
|
2003
|
| Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
|
Quartuccio L, Soardo G, Romano G, Zaja F, Scott C A, De Marchi G, Fabris M, Ferraccioli G, De Vita S
|
2006
|
| Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
|
Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londono MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W
|
2015 Oct 17
|
| Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
|
Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N
|
2017 Oct
|
| Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.
|
Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, Brancale J, Xu D, Wisocky J, Lin MV, Kim AY, Thadhani R, Chung RT
|
2017 Oct 6
|
| The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience.
|
Singh N, Neidlinger N, Djamali A, Leverson G, Voss B, Sollinger HW, Pirsch JD
|
2012 Sep-Oct
|
| Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts.
|
Scalea JR, Barth RN, Munivenkatappa R, Philosophe B, Cooper M, Whitlow V, LaMattina JC
|
2015 Jun
|
| Effect of antiviral therapy on hepatitis C virus related glomerulopathy.
|
Abbas G, Hussain S, Shafi T
|
2008 Sep
|
| Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.
|
Quartuccio L, Zuliani F, Corazza L, Scaini P, Zani R, Lenzi M, Tavoni A, Sebastiani M, Baldovino S, Urraro T, Saccardo F, Sbreglia C, Mazzaro C, Pioltelli P, Fraticelli P, Filippini D, Gabrielli A, Perrella O, Scarpato S, Roccatello D, Zignego AL, Ferri C, Bombardieri S, Pietrogrande M, Monti G, Galli M, De Vita S
|
2015 Sep
|
| Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
|
Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT
|
2016 Feb
|
| A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.
|
Sneller MC, Hu Z, Langford CA
|
2012 Mar
|
| Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis.
|
Mazzaro C, Panarello G, Mauro E, Gattei V, Pozzato G
|
2015 Jul
|
| Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
|
Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P
|
2006 Nov
|
| Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study.
|
Mazzaro C, Monti G, Saccardo F, Zignego AL, Ferri C, De Vita S, Gabrielli A, Lenzi M, Donada C, Galli M, Pietrogrande M, Pozzato G
|
2011 Nov-Dec
|
| Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
|
Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppere B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P
|
2010 Jul 22
|
| Real‐life efficacy and safety of glecaprevir/pibrentasvir in HCV‐infected patients with chronic kidney disease
|
Persico, M, Aglitti, A, Caruso, R, Calvanese, G, Di Siervi, P, Masarone, M
|
2019
|
| ‘Real-Life’ Experience With Direct-Acting Antiviral Agents For HCV After Kidney Transplant
|
Fabrizi Fabrizio, Alonso Cristina, Palazzo Ana, Anders Margarita, Reggiardo Maria Virginia, Cheinquer Hugo, Zuain Maria Grazia Videla, Figueroa Sebastian, Mendizabal Manuel, Silva Marcelo, Ridruejo Ezequiel, Latin American Liver Research, Educational and Awareness Network (LALREAN)
|
2021
|
| Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.
|
Molnar, Miklos Z, Azhar, Ambreen, Tsujita, Makoto, Talwar, Manish, Balaraman, Vasanthi, Bhalla, Anshul, Podila, Pradeep S B, Kothadia, Jiten, Agbim, Uchenna A, Maliakkal, Benedict, Satapathy, Sanjaya K, Kovesdy, Csaba P, Nair, Satheesh, Eason, James D
|
2021
|
| Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys.
|
Mazur, Rafal D, Abt, Peter L, Blumberg, Emily A, Bloom, Roy D, Reddy, K Rajender, Reese, Peter P, Goldberg, David S
|
2019
|
| Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.
|
McLean, Rhondalyn C, Reese Peter P, Acker Michael, Atluri Pavan, Bermudez Christian, Goldberg Lee R, Abt Peter L, Blumberg Emily A, Van Deerlin Vivianna M, Reddy K Rajender, Bloom Roy D, Hasz Richard, Suplee Lawrence, Sicilia Anna, Woodards Ashley, Zahid Muhammad Nauman, Bar Katharine J, Porrett Paige, Levine Matthew H, Hornsby Nicole, Gentile Caren, Smith Jennifer, Goldberg David S
|
2019
|
| Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks Is Safe and Effective in Patients Undergoing Dialysis
|
Chuang, W-L, et al.
|
2019
|
| Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
|
Liu Chen-Hua, Chen Chi-Yi, Su Wei-Wen, Tseng Kuo-Chih, Lo Ching-Chu, Liu Chun-Jen, Chen Jyh-Jou, Peng Cheng-Yuan, Shih Yu-Lueng, Yang Sheng-Shun, Huang Chia-Sheng, Huang Ke-Jhang, Chang Chi-Yang, Tsai Ming-Chang, Kao Wei-Yu, Fang Yo-Jen, Chen Po-Yueh, Su Pei-Yuan, Tseng Chih-Wei, Huang Jow-Jyh, Lee Pei-Lun, Lai Hsueh-Chou, Hsieh Tsai-Yuan, Chang Chung-Hsin, Huang Yi-Jie, Lee Fu-Jen, Chang Chun-Chao, Kao Jia-Horng
|
2021
|
| Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
|
Kirushnan, B, Shujauddin, MA, Arumugam, K, Ravichandran, R
|
2016
|
| Treatment outcomes of sofosbuvir and velpatasvir in chronic hepatitis C patients undergoing hemodialysis
|
Hussain, R, Butt, N, Rai, L, Ali, S, Khemani, H, Ullah, A
|
2021
|
| Impact of Direct Acting Antiviral Agents on kidney function in Hepatitis C Virus infected patients with chronic kidney disease
|
Sarhan, II, Mohamed OM, Hebah, HA, Ahmed, OA, Khedr, LE, Mahmoud, WA
|
2021
|
| Establishment of an outreach, grouping health care system to achieve micro-elimination of HCV for uremic patients in hemodialysis centers (ERASE-C)
|
Huang, C-F
|
2021
|
| Full dose Sofosbuvir-Velpatasvir in chronic Hepatitis C in patients with end stage renal disease
|
Ashraf, A, Shah, A, Khan, M, Maqsood Wani, M, Gulzar, GM, Singh, J, Parveen, S, Ahmad, N, Dar, H, Abdul Aziz, R, Dhar, N, Mushfiq Shafi, S, Tiwari, A
|
2021
|
| Long term follow-up in HCV infected patients with end stage chronic kidney disease after DAA therapy
|
Martinez-Camprecios, J, Muńoz Gómez, R, Londońo, MC, Roget, M, Serra, M, Escudero-Garcia, D, Puchades, L, Rodríguez, M, Losa-Garcia, JE, Gutierrez, ML, Carmona, I, Garcia-Samaniego Rey, FJ, Morano Amado, LE
|
2021
|
| Deferred direct-acting antiviral treatment in kidney transplantation from HCV-viremic donors into HCV-negative recipients
|
Pagano, G, Solà, E, Cańeta, N, Broquetas, T, Carrión, JA, Puigvehí, M, Coll, S, Garrido, E, Viu, A, Romero, J, Pérez, MJ, Zapatero, A, Bessa, X, Crespo Barrio, M, Garcia-Retortillo, M
|
2021
|
| 12 weeks treatment of Sofosbuvir/Velpatasvir in HCV negative recipients receiving renal transplantation from HCV positive donors
|
Chen, R, Li, D, Zhuang, S, Zhang, M, Yuan, X
|
2021
|
| Long-term effect of hcv eradication with direct acting antiviral (daas) therapy on egyptian patients with mixed cryglobulinemias (mc)
|
Elnadry, M, Mohamed, SF, Abdelhalem, MM, Elnoomany, K
|
2021
|
| Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.
|
Duerr Michael, Liefeldt Lutz, Friedersdorff Frank, Choi Mira, Öllinger Robert, Hofmann Jörg, Budde Klemens, Schrezenmeier Eva, Halleck Fabian
|
2020
|
| Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection.
|
Miyasaka Akio, Yoshida Yuichi, Murakami Akihiko, Hoshino Takao, Sawara Kei, Numao Hiroshi, Takikawa Yasuhiro
|
2022
|
| Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan.
|
Hu Tsung-Hui, Su Wei-Wen, Yang Chi-Chieh, Yang Chih-Chao, Kuo W-Hsien, Chen Yang-Yuan, Yeh Yung-Hsiang, Chen Shiou-Shiang, Tsao Yu-Yu, Chen Kwei-Ming, Yan Sheng-Lei, Lai Jun-Hung, Yao Chih-Da, Lim Cherng-Harng, Jen Hsiao Hsuan, Yeh Yen-Po, Chen Sam Li-Sheng, Chen Hsiu-Hsi, Chen Shih-Chung, Changhua Hepatitis C Elimination Task Force
|
2021
|
| Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR).
|
Huang Chung-Feng, Tseng Kuo-Chih, Cheng Pin-Nan, Hung Chao-Hung, Lo Ching-Chu, Peng Cheng-Yuan, Bair Ming-Jong, Yeh Ming-Lun, Chen Chien-Hung, Lee Pei-Lun, Lin Chun-Yen, Kuo Hsing-Tao, Chen Chun-Ting, Yang Chi-Chieh, Huang Jee-Fu, Tai Chi-Ming, Hu Jui-Ting, Lin Chih-Lang, Su Wei-Wen, Tsai Wei-Lun, Huang Yi-Hsiang, Cheng Chien-Yu, Lin Chih-Lin, Wang Chia-Chi, Yang Sheng-Shun, Mo Lein-Ray, Chen Guei-Ying, Chang Chun-Chao, Wang Szu-Jen, Huang Chia-Sheng, Hsieh Tsai-Yuan, Lin Chih-Wen, Lee Tzong-Hsi, Chong Lee-Won, Huang Chien-Wei, Chang Shiuh-Nan, Tsai Ming-Chang, Hsu Shih-Jer, Kao Jia-Horng, Liu Chun-Jen, Liu Chen-Hua, Lin Han-Chieh, Lee Mei-Hsuan, Tsai Pei-Chien, Dai Chia-Yen, Chuang Wan-Long, Chen Chi-Yi, Yu Ming-Lung
|
2021
|
| Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease.
|
Villani Rosanna, Romano Antonino Davide, Sangineto Moris, Serviddio Gaetano
|
2021
|
| Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort.
|
Calvaruso Vincenza, Petta Salvatore, Cacciola Irene, Cabibbo Giuseppe, Cartabellotta Fabio, Distefano Marco, Scifo Gaetano, Di Rosolini Maria Antonietta, Russello Maurizio, Prestileo Tullio, Madonia Salvatore, Malizia Giuseppe, Montineri Arturo, Digiacomo Antonio, Licata Anna, Benanti Francesco, Bertino Gaetano, Enea Marco, Battaglia Salvatore, Squadrito Giovanni, Raimondo Giovanni, Cammà Calogero, Craxì Antonio, Di Marco Vito, Rete Sicilia Selezione Terapia - HCV (RESIST-HCV)
|
2021
|
| Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals.
|
Chang Ming-Ling, Chang Su-Wei, Chen Shiang-Chi, Chien Rong-Nan, Hsu Chia-Lin, Chang Ming-Yu, Fann Cathy S J
|
2021
|
| Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life.
|
Gragnani Laura, Lorini Serena, Marri Silvia, Vacchi Caterina, Madia Francesco, Monti Monica, Ferri Clodoveo, Zignego Anna Linda
|
2022
|
| Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.
|
Gragnani Laura, Lorini Serena, Marri Silvia, Basile Umberto, Santarlasci Veronica, Monti Monica, Madia Francesco, Petraccia Luisa, Stasi Cristina, Marello Niccolò, Napodano Cecilia, Annunziato Francesco, Zignego Anna Linda
|
2021
|
| High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.
|
Ji Fanpu, Li Jie, Liu Li, Liang Jing, Wang Xiaozhong, Liu Junping, Cai Dachuan, Huang Rui, Zhang Jiajie, Wang Qi, Nan Yuemin, Li Junyi, Ye Qing, Zhang Mingyuan, Xu Qiang, Guo Feng, Zhao Changqing, Liu Lingdi, He Caini, Li Yu, Wang Wenjun, Kam Leslie Y, Tran Sally, Maeda Mayumi, Mizuta Akiko, Li Zongfang, Dang Shuangsuo, Ren Wanhua, Zhu Qiang, Cheung Ramsey, Niu Junqi, Xie Wen, Pan Hongying, Ren Hong, Wu Chao, Shang Jia, Wang Fengmei, Nguyen Mindie H
|
2021
|
| Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
|
Liu Chen-Hua, Chen Chi-Yi, Su Wei-Wen, Liu Chun-Jen, Lo Ching-Chu, Huang Ke-Jhang, Chen Jyh-Jou, Tseng Kuo-Chih, Chang Chi-Yang, Peng Cheng-Yuan, Shih Yu-Lueng, Huang Chia-Sheng, Kao Wei-Yu, Yang Sheng-Shun, Tsai Ming-Chang, Wu Jo-Hsuan, Chen Po-Yueh, Su Pei-Yuan, Hwang Jow-Jyh, Fang Yu-Jen, Lee Pei-Lun, Tseng Chi-Wei, Lee Fu-Jen, Lai Hsueh-Chou, Hsieh Tsai-Yuan, Chang Chun-Chao, Chang Chung-Hsin, Huang Yi-Jie, Kao Jia-Horng
|
2021
|
| Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study.
|
Su Pei-Yuan, Chen Yang-Yuan, Lai Jun-Hung, Chen Hung-Ming, Yao Chih-Ta, Liu I-Ling, Zeng Ya-Huei, Huang Siou-Ping, Hsu Yu-Chun, Wu Shun-Sheng, Siao Fu-Yuan, Yen Hsu-Heng
|
2021
|
| Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan.
|
Yamana Yoichiro, Kanda Tatsuo, Matsumoto Naoki, Honda Masayuki, Kumagawa Mariko, Sasaki Reina, Kanezawa Shini, Mizutani Taku, Yamagami Hiroaki, Masuzaki Ryota, Ishii Tomotaka, Nirei Kazushige, Moriyama Mitsuhiko
|
2021
|
| Transplantation of Hepatitis C-Infected Kidneys into Uninfected Recipients: A Review of the Literature.
|
Leesley Haley, Osband Adena J
|
2021
|
| Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis.
|
De Arka, Roy Akash, Verma Nipun, Mishra Saurabh, Premkumar Madhumita, Taneja Sunil, Singh Virendra, Duseja Ajay
|
2022
|
| An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
|
Majd Jabbari Sara, Maajani Khadije, Merat Shahin, Poustchi Hossein, Sepanlou Sadaf G
|
2021
|
| Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
|
Ji Qinghua, Chu Xudong, Zhou Yugui, Liu Xuan, Zhao Wei, Ye Wei
|
2022
|
| Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
|
Li Chunhong, Liang Jing, Xiang Huiling, Chen Haiyan, Tian Jie
|
2020
|
| The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection
|
Mostafi M, Jabin M, Chowdhury Z, Khondoker M, Ali S, Tamanna R, Rezwan R, Alomgir S
|
2022
|
| Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.
|
Cheng Pin-Nan, Mo Lein-Ray, Chen Chun-Ting, Chen Chi-Yi, Huang Chung-Feng, Kuo Hsing-Tao, Lo Ching-Chu, Tseng Kuo-Chih, Huang Yi-Hsiang, Tai Chi-Ming, Peng Cheng-Yuan, Bair Ming-Jong, Chen Chien-Hung, Yeh Ming-Lun, Lin Chih-Lang, Lin Chun-Yen, Lee Pei-Lun, Chong Lee-Won, Hung Chao-Hung, Chang Te Sheng, Huang Jee-Fu, Yang Chi-Chieh, Hu Jui-Ting, Lin Chih-Wen, Wang Chia-Chi, Su Wei-Wen, Hsieh Tsai-Yuan, Lin Chih-Lin, Tsai Wei-Lun, Lee Tzong-Hsi, Chen Guei-Ying, Wang Szu-Jen, Chang Chun-Chao, Yang Sheng-Shun, Wu Wen-Chih, Huang Chia-Sheng, Chou Kwok-Hsiung, Kao Chien-Neng, Tsai Pei-Chien, Liu Chen-Hua, Lee Mei-Hsuan, Cheng Chien-Yu, Tsai Ming-Chang, Liu Chun-Jen, Dai Chia-Yen, Lin Han-Chieh, Kao Jia-Horng, Chuang Wan-Long, Yu Ming-Lung, TACR investigators
|
2022
|
| Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
|
Yu Ming-Lung, Huang Chung-Feng, Wei Yu-Ju, Lin Wen-Yi, Lin Yi-Hung, Hsu Po-Yao, Hsu Cheng-Ting, Liu Ta Wei, Lee Jia-Jung, Niu Sheng-Wen, Huang Jiun-Chi, Hung Tzu-Sui, Yeh Ming-Lun, Huang Ching-I, Liang Po-Cheng, Hsieh Ming-Yen, Chen Szu-Chia, Huang Jee-Fu, Chang Jer-Ming, Chiu Yi-Wen, Dai Chia-Yen, Hwang Shang-Jyh, Chuang Wan-Long, FORMOSA-LIKE investigators
|
2021
|
| Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.
|
Lai Ping-Chin, Chen Cheng-Hsu, Jeng Long-Bin, Yu Tung-Min, Tsai Shang-Feng, Wu Ming-Ju, Cheng Shao-Bin, Yang Sheng-Shun, Lee Teng-Yu
|
2022
|
| Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors.
|
Chen Ruoyang, Li Dawei, Zhang Ming, Yuan Xiaodong
|
2021
|
| Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting.
|
Concepcion Beatrice P, Binari Laura A, Schaefer Heidi, Rega Scott, Feurer Irene, Shawar Saed, Naik Ruchi, Hickman Laura, Walker Jasmine, Kapp Meghan, Birdwell Kelly A, Langone Anthony, Helderman J Harold, Ann Sarrell Bonnie, Kochar Guneet, Dubray Bernard, Smith Kristin, O'Dell Heather, DeMers April, Shelton Princess, Perri Roman, Shaffer David, Forbes Rachel C
|
2021
|
| Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
|
Gupta Gaurav, Yakubu Idris, Zhang Yiran, Kimball Pamela, Kang Le, Mitchell Kimberly, Ijioma Stephen, Carroll Norman, Patterson Julie, Shinbashi Meagan, Kumar Dhiren, Moinuddin Irfan, Kamal Layla, King Anne, Bhati Chandra, Levy Marlon, Cotterell Adrian, Khan Aamir, Sharma Amit, Sterling Richard
|
2021
|
| A real-world, single-center experience of the utilization of hepatitis C-viremic kidneys for hepatitis C-negative recipients.
|
Daloul Reem, Anthony Michaels, Washburn Kenneth, Singh Priyamvada, Pesavento Todd
|
2021
|
| Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.
|
Tronina Olga, Durlik Magdalena, Orłowska Iwona, Lorenc Beata, Łapiński Tadeusz W, Garlicki Aleksander, Dybowska Dorota, Zarębska-Michaluk Dorota, Tudrujek-Zdunek Magdalena, Citko Jolanta, Janczewska Ewa, Kaczmarczyk Marcin, Jaroszewicz Jerzy, Krygier Rafał, Klapaczyński Jakub, Dobracka Beata, Białkowska-Warzecha Jolanta, Piekarska Anna, Simon Krzysztof, Halota Waldemar, Pawłowska Małgorzata, Tomasiewicz Krzysztof, Flisiak Robert
|
2021
|
| Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation.
|
Hudson Madeline R, Webb Allyssa R, Logan Angela Tong, Silverman Andrew, Brueckner Andrew J
|
2021
|
| Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
|
Lo Ching-Chu, Huang Chung-Feng, Cheng Pin-Nan, Tseng Kuo-Chih, Chen Chi-Yi, Kuo Hsing-Tao, Huang Yi-Hsiang, Tai Chi-Ming, Peng Cheng-Yuan, Bair Ming-Jong, Chen Chien-Hung, Yeh Ming-Lun, Lin Chih-Lang, Lin Chun-Yen, Lee Pei-Lun, Chong Lee-Won, Hung Chao-Hung, Chang Te Sheng, Huang Jee-Fu, Yang Chi-Chieh, Hu Jui-Ting, Lin Chih-Wen, Chen Chun-Ting, Wang Chia-Chi, Su Wei-Wen, Hsieh Tsai-Yuan, Lin Chih-Lin, Tsai Wei-Lun, Lee Tzong-Hsi, Chen Guei-Ying, Wang Szu-Jen, Chang Chun-Chao, Mo Lein-Ray, Yang Sheng-Shun, Wu Wen-Chih, Huang Chia-Sheng, Hsiung Chou-Kwok, Kao Chien-Neng, Tsai Pei-Chien, Liu Chen-Hua, Lee Mei-Hsuan, Liu Chun-Jen, Dai Chia-Yen, Chuang Wan-Long, Lin Han-Chieh, Kao Jia-Horng, Yu Ming-Lung, TACR investigators
|
2022
|
| A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort.
|
Kondili Loreta A, Monti Monica, Quaranta Maria Giovanna, Gragnani Laura, Panetta Valentina, Brancaccio Giuseppina, Mazzaro Cesare, Persico Marcello, Masarone Mario, Gentile Ivan, Andreone Pietro, Madonia Salvatore, Biliotti Elisa, Filomia Roberto, Puoti Massimo, Fracanzani Anna Ludovica, Laccabue Diletta, Ieluzzi Donatella, Coppola Carmine, Rumi Maria Grazia, Benedetti Antonio, Verucchi Gabriella, Coco Barbara, Chemello Liliana, Iannone Andrea, Ciancio Alessia, Russo Francesco Paolo, Barbaro Francesco, Morisco Filomena, Chessa Luchino, Massari Marco, Blanc Pierluigi, Zignego Anna Linda
|
2021
|
| One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.
|
Sise Meghan Elizabeth, Goldberg David Seth, Schaubel Douglas Earl, Fontana Robert J, Kort Jens J, Alloway Rita R, Durand Christine M, Blumberg Emily A, Woodle E Steve, Sherman Kenneth E, Brown Robert S, Friedewald John J, Desai Niraj M, Sultan Samuel T, Levitsky Josh, Lee Meghan D, Strohbehn Ian A, Landis J Richard, Fernando Melissa, Gustafson Jenna L, Chung Raymond T, Reese Peter Philip
|
2022
|
| Relapse of HCV-Cryoglobulinemic Vasculitis Following Sustained Viral Response after Interferon-free Direct-Acting Antivirals.
|
Fayed Ahmed, Hegazy Mohamed Tharwat, Biard Lucie, Vieira Matheus, El Shabony Tarek, Saadoun David, Casato Milvia, Visentini Marcella, Ragab Gaafar, Cacoub Patrice
|
2022
|
| Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome.
|
Zignego Anna L, Marri Silvia, Gragnani Laura
|
2021
|